|
G |
1700037C18Rik |
RIKEN cDNA 1700037C18 gene |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in increased expression of C10H16ORF90 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr16:3,723,662...3,726,553
Ensembl chr16:3,713,043...3,726,553
|
|
G |
Abhd2 |
abhydrolase domain containing 2 |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of ABHD2 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 7:78,923,002...79,015,257
Ensembl chr 7:78,922,947...79,015,256
|
|
G |
Ablim1 |
actin-binding LIM protein 1 |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of ABLIM1 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr19:57,021,165...57,303,776
Ensembl chr19:57,021,165...57,303,351
|
|
G |
Acads |
acyl-Coenzyme A dehydrogenase, short chain |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in increased expression of ACADS mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 5:115,248,358...115,257,405
Ensembl chr 5:115,248,358...115,257,405
|
|
G |
Adam10 |
a disintegrin and metallopeptidase domain 10 |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of ADAM10 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 9:70,586,133...70,687,511
Ensembl chr 9:70,586,279...70,687,511
|
|
G |
Adar |
adenosine deaminase, RNA-specific |
affects localization |
ISO |
Poly I-C affects the localization of ADAR protein |
CTD |
PMID:22240577 |
|
NCBI chr 3:89,622,321...89,660,756
Ensembl chr 3:89,622,329...89,660,753
|
|
G |
Ahcyl1 |
S-adenosylhomocysteine hydrolase-like 1 |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of AHCYL1 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 3:107,570,436...107,603,876
Ensembl chr 3:107,570,434...107,603,876
|
|
G |
Ahr |
aryl-hydrocarbon receptor |
increases expression |
ISO |
Poly I-C results in increased expression of AHR mRNA; Poly I-C results in increased expression of AHR protein |
CTD |
PMID:27783115 |
|
NCBI chr12:35,547,978...35,584,988
Ensembl chr12:35,547,973...35,585,037
|
|
G |
Akap5 |
A kinase anchor protein 5 |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of AKAP5 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr12:76,371,652...76,380,925
Ensembl chr12:76,371,665...76,380,927
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of APP mRNA |
CTD |
PMID:26923065 |
|
NCBI chr16:84,751,236...84,972,187
Ensembl chr16:84,746,573...84,970,654
|
|
G |
Appl1 |
adaptor protein, phosphotyrosine interaction, PH domain and leucine zipper containing 1 |
increases degradation multiple interactions |
EXP |
Poly I-C results in increased degradation of APPL1 protein APPL1 protein inhibits the reaction [Poly I-C results in increased expression of IL1B protein]; APPL1 protein inhibits the reaction [Poly I-C results in increased expression of TNF protein]; APPL1 protein promotes the reaction [Poly I-C results in increased expression of CCL5 mRNA]; APPL1 protein promotes the reaction [Poly I-C results in increased expression of CXCL10 mRNA]; APPL1 protein promotes the reaction [Poly I-C results in increased expression of IFNB1 mRNA]; APPL1 protein promotes the reaction [Poly I-C results in increased phosphorylation of IKBKE protein]; APPL1 protein promotes the reaction [Poly I-C results in increased phosphorylation of IRF3 protein]; APPL1 protein promotes the reaction [Poly I-C results in increased phosphorylation of TBK1 protein]; bafilomycin A1 promotes the reaction [Poly I-C results in increased degradation of APPL1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Poly I-C results in increased degradation of APPL1 protein]; Chloroquine inhibits the reaction [Poly I-C results in increased degradation of APPL1 protein]; trametinib inhibits the reaction [Poly I-C results in increased degradation of APPL1 protein]; U 0126 inhibits the reaction [Poly I-C results in increased degradation of APPL1 protein] |
CTD |
PMID:25780039 |
|
NCBI chr14:26,640,943...26,692,567
Ensembl chr14:26,640,945...26,693,189
|
|
G |
Arc |
activity regulated cytoskeletal-associated protein |
affects methylation |
ISO |
Poly I-C affects the methylation of ARC promoter |
CTD |
PMID:32843831 |
|
NCBI chr15:74,540,930...74,544,419
Ensembl chr15:74,540,932...74,544,419
|
|
G |
Arfgef3 |
ARFGEF family member 3 |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of ARFGEF3 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr10:18,463,759...18,619,506
Ensembl chr10:18,457,587...18,619,697
|
|
G |
Arg2 |
arginase type II |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in increased expression of ARG2 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr12:79,177,562...79,203,075
Ensembl chr12:79,177,551...79,203,075
|
|
G |
Arhgap11a |
Rho GTPase activating protein 11A |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in increased expression of ARHGAP11A mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 2:113,661,837...113,679,006
Ensembl chr 2:113,661,837...113,679,006
|
|
G |
Arhgap44 |
Rho GTPase activating protein 44 |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of ARHGAP44 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr11:64,892,865...65,053,779
Ensembl chr11:64,892,865...65,053,787
|
|
G |
Arhgap9 |
Rho GTPase activating protein 9 |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in increased expression of ARHGAP9 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr10:127,157,829...127,165,816
Ensembl chr10:127,157,833...127,165,812
|
|
G |
Arhgef12 |
Rho guanine nucleotide exchange factor 12 |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of ARHGEF12 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 9:42,875,138...43,017,069
Ensembl chr 9:42,875,138...43,018,534
|
|
G |
Arhgef7 |
Rho guanine nucleotide exchange factor |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of ARHGEF7 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 8:11,778,053...11,885,219
Ensembl chr 8:11,777,721...11,885,219
|
|
G |
Arsb |
arylsulfatase B |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of ARSB mRNA |
CTD |
PMID:26923065 |
|
NCBI chr13:93,908,187...94,079,524
Ensembl chr13:93,908,138...94,079,524
|
|
G |
Art3 |
ADP-ribosyltransferase 3 |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in increased expression of ART3 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 5:92,479,659...92,562,487
Ensembl chr 5:92,479,686...92,562,487
|
|
G |
Atf3 |
activating transcription factor 3 |
increases expression |
ISO |
Poly I-C results in increased expression of ATF3 mRNA |
CTD |
PMID:27783115 |
|
NCBI chr 1:190,902,493...190,915,530
Ensembl chr 1:190,902,493...190,950,236
|
|
G |
Atp2b2 |
ATPase, Ca++ transporting, plasma membrane 2 |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of ATP2B2 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 6:113,720,803...114,019,574
Ensembl chr 6:113,720,792...114,019,574
|
|
G |
Atxn3 |
ataxin 3 |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of ATXN3 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr12:101,885,160...101,928,139
Ensembl chr12:101,885,160...101,924,505
|
|
G |
Bax |
BCL2-associated X protein |
increases expression |
ISO |
Poly I-C results in increased expression of BAX protein |
CTD |
PMID:21418039 |
|
NCBI chr 7:45,111,124...45,116,332
Ensembl chr 7:45,111,121...45,116,322
|
|
G |
Bcl2 |
B cell leukemia/lymphoma 2 |
decreases expression |
ISO |
Poly I-C results in decreased expression of BCL2 protein |
CTD |
PMID:21418039 |
|
NCBI chr 1:106,465,906...106,642,020
Ensembl chr 1:106,465,908...106,642,004
|
|
G |
Bcl2a1b |
B cell leukemia/lymphoma 2 related protein A1b |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in increased expression of BCL2A1 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 9:89,081,326...89,089,891
Ensembl chr 9:89,081,262...89,089,880
|
|
G |
Bdnf |
brain derived neurotrophic factor |
multiple interactions affects methylation |
EXP ISO |
[Poly I-C results in increased susceptibility to 4-iodo-2,5-dimethoxyphenylisopropylamine] which results in increased expression of BDNF mRNA; Poly I-C promotes the reaction [4-iodo-2,5-dimethoxyphenylisopropylamine results in increased expression of BDNF mRNA] Poly I-C affects the methylation of BDNF promoter |
CTD |
PMID:24889602 PMID:32843831 |
|
NCBI chr 2:109,505,045...109,557,388
Ensembl chr 2:109,505,045...109,557,352
|
|
G |
Bid |
BH3 interacting domain death agonist |
decreases expression |
ISO |
Poly I-C results in decreased expression of BID protein |
CTD |
PMID:21418039 |
|
NCBI chr 6:120,870,080...120,894,074
Ensembl chr 6:120,868,891...120,893,814
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
multiple interactions |
ISO |
Poly I-C promotes the reaction [arsenic trioxide results in decreased expression of BIRC5 protein] |
CTD |
PMID:21418039 |
|
NCBI chr11:117,740,063...117,746,569
Ensembl chr11:117,740,077...117,746,569
|
|
G |
Birc6 |
baculoviral IAP repeat-containing 6 |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in increased expression of BIRC6 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr17:74,835,247...75,010,351
Ensembl chr17:74,835,290...75,010,351
|
|
G |
Blmh |
bleomycin hydrolase |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in increased expression of BLMH mRNA |
CTD |
PMID:26923065 |
|
NCBI chr11:76,836,482...76,878,215
Ensembl chr11:76,815,635...76,878,205
|
|
G |
Bltp1 |
bridge-like lipid transfer protein family member 1 |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of BLTP1 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 3:36,917,212...37,107,182
Ensembl chr 3:36,917,253...37,107,182
|
|
G |
Brms1l |
breast cancer metastasis-suppressor 1-like |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of BRMS1L mRNA |
CTD |
PMID:26923065 |
|
NCBI chr12:55,883,109...55,916,521
Ensembl chr12:55,883,109...55,916,521
|
|
G |
Brox |
BRO1 domain and CAAX motif containing |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of BROX mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 1:183,057,916...183,078,839
Ensembl chr 1:183,057,916...183,078,813
|
|
G |
C1qtnf7 |
C1q and tumor necrosis factor related protein 7 |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in increased expression of C1QTNF7 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 5:43,672,792...43,776,805
Ensembl chr 5:43,672,881...43,776,145
|
|
G |
Cage1 |
cancer antigen 1 |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in increased expression of CAGE1 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr13:38,190,028...38,221,115
Ensembl chr13:38,190,028...38,221,045
|
|
G |
Car3 |
carbonic anhydrase 3 |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in increased expression of CA3 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 3:14,928,598...14,937,441
Ensembl chr 3:14,928,572...14,937,583
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases activity |
ISO |
Acetylcysteine inhibits the reaction [arsenic trioxide promotes the reaction [Poly I-C results in increased activity of CASP3 protein]]; Acetylcysteine inhibits the reaction [Poly I-C promotes the reaction [arsenic trioxide results in increased activity of CASP3 protein]]; arsenic trioxide promotes the reaction [Poly I-C results in increased activity of CASP3 protein]; Poly I-C promotes the reaction [arsenic trioxide results in increased activity of CASP3 protein] |
CTD |
PMID:21418039 |
|
NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724
|
|
G |
Casp8 |
caspase 8 |
multiple interactions increases activity |
ISO |
arsenic trioxide promotes the reaction [Poly I-C results in increased activity of CASP8 protein]; Poly I-C promotes the reaction [arsenic trioxide results in increased activity of CASP8 protein] |
CTD |
PMID:21418039 |
|
NCBI chr 1:58,834,553...58,886,663
Ensembl chr 1:58,834,533...58,886,662
|
|
G |
Casp9 |
caspase 9 |
multiple interactions increases activity |
ISO |
Acetylcysteine inhibits the reaction [arsenic trioxide promotes the reaction [Poly I-C results in increased activity of CASP9 protein]]; Acetylcysteine inhibits the reaction [Poly I-C promotes the reaction [arsenic trioxide results in increased activity of CASP9 protein]]; arsenic trioxide promotes the reaction [Poly I-C results in increased activity of CASP9 protein]; Poly I-C promotes the reaction [arsenic trioxide results in increased activity of CASP9 protein] |
CTD |
PMID:21418039 |
|
NCBI chr 4:141,520,923...141,543,289
Ensembl chr 4:141,520,923...141,543,287
|
|
G |
Cat |
catalase |
decreases expression |
ISO |
Poly I-C results in decreased expression of CAT mRNA |
CTD |
PMID:23939143 |
|
NCBI chr 2:103,284,249...103,315,498
Ensembl chr 2:103,284,194...103,315,505
|
|
G |
Cav1 |
caveolin 1, caveolae protein |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of CAV1 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 6:17,306,387...17,341,323
Ensembl chr 6:17,306,334...17,341,451
|
|
G |
Cbx1 |
chromobox 1 |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in increased expression of CBX1 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr11:96,679,506...96,699,808
Ensembl chr11:96,679,953...96,699,466
|
|
G |
Cbx6 |
chromobox 6 |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of CBX6 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr15:79,708,099...79,718,534
Ensembl chr15:79,708,097...79,718,889
|
|
G |
Ccdc113 |
coiled-coil domain containing 113 |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in increased expression of CCDC113 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 8:96,260,684...96,285,516
Ensembl chr 8:96,260,713...96,285,518
|
|
G |
Ccl1 |
C-C motif chemokine ligand 1 |
increases expression |
ISO |
Poly I-C results in increased expression of CCL1 mRNA |
CTD |
PMID:27783115 |
|
NCBI chr11:82,067,492...82,070,638
Ensembl chr11:82,067,483...82,196,516
|
|
G |
Ccl11 |
C-C motif chemokine ligand 11 |
multiple interactions increases secretion |
EXP |
methyldithiocarbamate inhibits the reaction [Poly I-C results in increased secretion of CCL11 protein] |
CTD |
PMID:24056979 |
|
NCBI chr11:81,948,658...81,953,781
Ensembl chr11:81,948,649...81,953,781
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions increases secretion increases expression |
EXP ISO |
methyldithiocarbamate inhibits the reaction [Poly I-C results in increased secretion of CCL2 protein] Poly I-C results in increased expression of CCL2 mRNA |
CTD |
PMID:23939143 PMID:24056979 PMID:34740670 |
|
NCBI chr11:81,926,403...81,928,278
Ensembl chr11:81,926,397...81,928,279
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
multiple interactions increases expression |
EXP |
Ethanol inhibits the reaction [Poly I-C results in increased expression of CCL3 protein] |
CTD |
PMID:19500611 |
|
NCBI chr11:83,538,669...83,540,204
Ensembl chr11:83,538,670...83,540,181
|
|
G |
Ccl4 |
C-C motif chemokine ligand 4 |
multiple interactions increases expression increases secretion |
EXP ISO |
Ethanol inhibits the reaction [Poly I-C results in increased expression of CCL4 protein]; methyldithiocarbamate inhibits the reaction [Poly I-C results in increased secretion of CCL4 protein] Poly I-C results in increased expression of CCL4 mRNA 6-formylindolo(3,2-b)carbazole inhibits the reaction [Poly I-C results in increased expression of CCL4 mRNA]; Tetrachlorodibenzodioxin inhibits the reaction [Poly I-C results in increased expression of CCL4 mRNA] |
CTD |
PMID:19500611 PMID:24056979 PMID:27783115 |
|
NCBI chr11:83,553,410...83,555,509
Ensembl chr11:83,553,410...83,555,509
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
multiple interactions increases secretion increases expression |
EXP ISO |
APPL1 protein promotes the reaction [Poly I-C results in increased expression of CCL5 mRNA]; methyldithiocarbamate inhibits the reaction [Poly I-C results in increased secretion of CCL5 protein]; trametinib promotes the reaction [Poly I-C results in increased expression of CCL5 mRNA] 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CCL5 mRNA]; [Poly I-C co-treated with IL4 protein] results in increased expression of CCL5 mRNA; amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CCL5 mRNA]; butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CCL5 mRNA]; helenalin inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CCL5 mRNA]; IL4 protein promotes the reaction [Poly I-C results in increased expression of CCL5 mRNA]; Itraconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CCL5 mRNA]; Ketoconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CCL5 mRNA]; luliconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CCL5 mRNA]; Particulate Matter inhibits the reaction [Poly I-C results in increased expression of CCL5]; Terbinafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CCL5 mRNA]; Vehicle Emissions inhibits the reaction [Poly I-C results in increased expression of CCL5] Poly I-C results in increased expression of CCL5; Poly I-C results in increased expression of CCL5 mRNA |
CTD |
PMID:23688403 PMID:24056979 PMID:24709138 PMID:25780039 |
|
NCBI chr11:83,416,604...83,421,344
Ensembl chr11:83,416,604...83,421,344
|
|
G |
Cd40 |
CD40 antigen |
increases expression multiple interactions |
ISO |
Poly I-C results in increased expression of CD40 protein [Poly I-C co-treated with IFNG protein] results in increased secretion of CD40 protein |
CTD |
PMID:15246609 PMID:16224278 |
|
NCBI chr 2:164,897,535...164,913,574
Ensembl chr 2:164,897,547...164,914,868
|
|
G |
Cd80 |
CD80 antigen |
increases expression |
ISO |
Poly I-C results in increased expression of CD80 protein |
CTD |
PMID:15246609 |
|
NCBI chr16:38,277,793...38,316,682
Ensembl chr16:38,275,923...38,316,697
|
|
G |
Cd83 |
CD83 antigen |
increases expression multiple interactions |
ISO |
Poly I-C results in increased expression of CD83 protein CEP-11004 inhibits the reaction [Poly I-C results in increased expression of CD83 protein]; SB 203580 inhibits the reaction [Poly I-C results in increased expression of CD83 protein] |
CTD |
PMID:17698565 |
|
NCBI chr13:43,938,661...43,956,608
Ensembl chr13:43,938,251...43,956,608
|
|
G |
Cd86 |
CD86 antigen |
multiple interactions increases expression |
ISO |
[Poly I-C co-treated with IFNG protein] results in increased secretion of CD86 protein; CEP-11004 inhibits the reaction [Poly I-C results in increased expression of CD86 protein]; Particulate Matter analog inhibits the reaction [Poly I-C results in increased expression of CD86 protein]; SB 203580 inhibits the reaction [Poly I-C results in increased expression of CD86 protein]; Vehicle Emissions analog inhibits the reaction [Poly I-C results in increased expression of CD86 protein] |
CTD |
PMID:15246609 PMID:16224278 PMID:16890772 PMID:17698565 |
|
NCBI chr16:36,389,318...36,486,439
Ensembl chr16:36,424,231...36,486,443
|
|
G |
Cdc42 |
cell division cycle 42 |
multiple interactions |
ISO |
[Poly I-C co-treated with Atorvastatin] results in decreased expression of CDC42 mRNA |
CTD |
PMID:34696514 |
|
NCBI chr 4:137,047,011...137,085,007
Ensembl chr 4:137,047,007...137,085,031
|
|
G |
Cdx2 |
caudal type homeobox 2 |
multiple interactions |
ISO |
[Poly I-C co-treated with 6-formylindolo(3,2-b)carbazole] results in increased expression of CDX2 mRNA; [Poly I-C co-treated with Tetrachlorodibenzodioxin] results in increased expression of CDX2 mRNA |
CTD |
PMID:27783115 |
|
NCBI chr 5:147,237,710...147,244,059
Ensembl chr 5:147,237,615...147,244,080
|
|
G |
Celf1 |
CUGBP, Elav-like family member 1 |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of CELF1 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 2:90,770,604...90,849,842
Ensembl chr 2:90,770,727...90,849,842
|
|
G |
Cfp |
complement factor properdin |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in increased expression of CFP mRNA |
CTD |
PMID:26923065 |
|
NCBI chr X:20,791,693...20,797,794
Ensembl chr X:20,791,693...20,797,794
|
|
G |
Chsy1 |
chondroitin sulfate synthase 1 |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of CHSY1 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 7:65,759,240...65,823,546
Ensembl chr 7:65,759,263...65,823,546
|
|
G |
Cibar2 |
CBY1 interacting BAR domain containing 2 |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in increased expression of CIBAR2 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 8:120,893,136...120,904,225
Ensembl chr 8:120,893,136...120,904,205
|
|
G |
Clcc1 |
chloride channel CLIC-like 1 |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in increased expression of CLCC1 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 3:108,561,194...108,586,156
Ensembl chr 3:108,561,229...108,586,156
|
|
G |
Clec14a |
C-type lectin domain family 14, member a |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in increased expression of CLEC14A mRNA |
CTD |
PMID:26923065 |
|
NCBI chr12:58,311,506...58,316,044
Ensembl chr12:58,311,506...58,316,076
|
|
G |
Clip3 |
CAP-GLY domain containing linker protein 3 |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of CLIP3 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 7:29,991,120...30,007,792
Ensembl chr 7:29,991,153...30,007,792
|
|
G |
Cnnm1 |
cyclin M1 |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of CNNM1 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr19:43,427,508...43,485,649
Ensembl chr19:43,428,875...43,485,649
|
|
G |
Cnr1 |
cannabinoid receptor 1 |
multiple interactions |
ISO |
Cannabidiol inhibits the reaction [Poly I-C inhibits the reaction [Rimonabant binds to CNR1 protein]]; Poly I-C inhibits the reaction [Rimonabant binds to CNR1 protein] |
CTD |
PMID:31202911 |
|
NCBI chr 4:33,923,171...33,948,831
Ensembl chr 4:33,924,593...33,948,831
|
|
G |
Cnr2 |
cannabinoid receptor 2 |
increases expression |
ISO |
Poly I-C results in increased expression of CNR2 mRNA |
CTD |
PMID:27317300 |
|
NCBI chr 4:135,622,500...135,647,530
Ensembl chr 4:135,622,705...135,647,518
|
|
G |
Cntn1 |
contactin 1 |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of CNTN1 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr15:91,949,034...92,239,834
Ensembl chr15:91,949,046...92,239,848
|
|
G |
Crabp1 |
cellular retinoic acid binding protein I |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in increased expression of CRABP1 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 9:54,672,032...54,680,394
Ensembl chr 9:54,672,032...54,680,394
|
|
G |
Csf2 |
colony stimulating factor 2 (granulocyte-macrophage) |
multiple interactions increases expression increases secretion |
EXP ISO |
Ethanol inhibits the reaction [Poly I-C results in increased expression of CSF2 protein] Smoke inhibits the reaction [Poly I-C results in increased secretion of CSF2 protein] |
CTD |
PMID:19500611 PMID:35817128 |
|
NCBI chr11:54,138,096...54,140,725
Ensembl chr11:54,138,097...54,140,493
|
|
G |
Cttnbp2 |
cortactin binding protein 2 |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of CTTNBP2 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 6:18,366,470...18,515,216
Ensembl chr 6:18,366,477...18,514,842
|
|
G |
Cxcl1 |
C-X-C motif chemokine ligand 1 |
increases expression |
ISO |
Poly I-C results in increased expression of CXCL1 mRNA |
CTD |
PMID:23939143 |
|
NCBI chr 5:91,039,104...91,040,980
Ensembl chr 5:91,039,100...91,040,974
|
|
G |
Cxcl10 |
C-X-C motif chemokine ligand 10 |
multiple interactions increases expression increases secretion |
EXP ISO |
APPL1 protein promotes the reaction [Poly I-C results in increased expression of CXCL10 mRNA]; chrysin inhibits the reaction [Poly I-C results in increased expression of CXCL10 mRNA]; eriodictyol inhibits the reaction [Poly I-C results in increased expression of CXCL10 mRNA]; Luteolin inhibits the reaction [Poly I-C results in increased expression of CXCL10 mRNA]; Quercetin inhibits the reaction [Poly I-C results in increased expression of CXCL10 mRNA]; trametinib promotes the reaction [Poly I-C results in increased expression of CXCL10 mRNA] Poly I-C results in increased expression of CXCL10 mRNA; Poly I-C results in increased expression of CXCL10 protein [Dronabinol co-treated with Cannabidiol] inhibits the reaction [Poly I-C results in increased expression of CXCL10 protein]; [Pam(3)CSK(4) peptide co-treated with Antigens, Bacterial co-treated with Poly I-C co-treated with Lipopolysaccharides co-treated with FSL-1 lipoprotein, synthetic co-treated with Imiquimod co-treated with Polyribonucleotides co-treated with ProMune] results in increased expression of CXCL10 protein; bafilomycin A1 inhibits the reaction [Poly I-C results in increased expression of CXCL10 protein]; Cannabidiol inhibits the reaction [Poly I-C results in increased expression of CXCL10 mRNA]; Cannabidiol inhibits the reaction [Poly I-C results in increased expression of CXCL10 protein]; Cannabidiol inhibits the reaction [Poly I-C results in increased secretion of CXCL10 protein]; Chloroquine inhibits the reaction [Poly I-C results in increased expression of CXCL10 protein]; Dronabinol inhibits the reaction [Poly I-C results in increased expression of CXCL10 mRNA]; Dronabinol inhibits the reaction [Poly I-C results in increased expression of CXCL10 protein]; Particulate Matter inhibits the reaction [[Pam(3)CSK(4) peptide co-treated with Antigens, Bacterial co-treated with Poly I-C co-treated with Lipopolysaccharides co-treated with FSL-1 lipoprotein, synthetic co-treated with Imiquimod co-treated with Polyribonucleotides co-treated with ProMune] results in increased expression of CXCL10 protein]; Phosphorothioate Oligonucleotides inhibits the reaction [Poly I-C results in increased expression of CXCL10 protein]; Smoke inhibits the reaction [Poly I-C results in increased expression of CXCL10 protein]; Smoke inhibits the reaction [Poly I-C results in increased secretion of CXCL10 protein]; Vehicle Emissions inhibits the reaction [[Pam(3)CSK(4) peptide co-treated with Antigens, Bacterial co-treated with Poly I-C co-treated with Lipopolysaccharides co-treated with FSL-1 lipoprotein, synthetic co-treated with Imiquimod co-treated with Polyribonucleotides co-treated with ProMune] results in increased expression of CXCL10 protein] cyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl ester inhibits the reaction [Poly I-C results in increased expression of CXCL10 mRNA] |
CTD |
PMID:19426678 PMID:25780039 PMID:26682054 PMID:28003376 PMID:28572013 PMID:28655636 PMID:28726298 PMID:32244040 PMID:34740670 PMID:35817128 PMID:36958387 More...
|
|
NCBI chr 5:92,494,497...92,496,748
Ensembl chr 5:92,494,497...92,496,748
|
|
G |
Cxcl15 |
C-X-C motif chemokine ligand 15 |
multiple interactions increases secretion increases expression |
ISO |
1,3-bis(4-hydroxyphenyl)-4-methyl-5-(4-(2-piperidinylethoxy)phenol)-1H-pyrazole inhibits the reaction [Estradiol promotes the reaction [Poly I-C results in increased expression of CXCL8 protein]]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CXCL8 mRNA]; 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane promotes the reaction [Poly I-C results in increased expression of CXCL8 protein]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Poly I-C results in increased secretion of CXCL8 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Poly I-C results in increased secretion of CXCL8 protein]; 4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol promotes the reaction [Poly I-C results in increased expression of CXCL8 protein]; [Poly I-C co-treated with IL4 protein] results in increased expression of CXCL8 mRNA; amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CXCL8 mRNA]; butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CXCL8 mRNA]; CpG ODN 2006 inhibits the reaction [Poly I-C results in increased secretion of CXCL8 protein]; Estradiol promotes the reaction [Poly I-C results in increased expression of CXCL8 protein]; helenalin inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CXCL8 mRNA]; IL4 protein promotes the reaction [Poly I-C results in increased expression of CXCL8 mRNA]; Itraconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CXCL8 mRNA]; Ketoconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CXCL8 mRNA]; luliconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CXCL8 mRNA]; N-(3,5-bis(trifluoromethyl)phenyl)-5-chloro-2-hydroxybenzamide inhibits the reaction [Poly I-C results in increased secretion of CXCL8 protein]; Particulate Matter promotes the reaction [Poly I-C results in increased expression of CXCL8]; Poly I-C affects the reaction [Gold Sodium Thiosulfate results in increased secretion of CXCL8 protein]; pyrazolanthrone inhibits the reaction [Poly I-C results in increased secretion of CXCL8 protein]; RTKI cpd inhibits the reaction [Poly I-C results in increased secretion of CXCL8 protein]; SB 203580 inhibits the reaction [Poly I-C results in increased secretion of CXCL8 protein]; Smoke inhibits the reaction [Poly I-C results in increased secretion of CXCL8 protein]; Terbinafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CXCL8 mRNA]; TLR3 protein affects the reaction [Poly I-C results in increased expression of CXCL8 mRNA]; TP53 protein affects the reaction [Poly I-C results in increased expression of CXCL8 mRNA]; Vehicle Emissions promotes the reaction [Poly I-C results in increased expression of CXCL8]; Vehicle Emissions promotes the reaction [Poly I-C results in increased secretion of CXCL8 protein] Poly I-C results in increased expression of CXCL8; Poly I-C results in increased expression of CXCL8 mRNA; Poly I-C results in increased expression of CXCL8 protein |
CTD |
PMID:17669408 PMID:18779317 PMID:20932985 PMID:23618096 PMID:23688403 PMID:24709138 PMID:25458486 PMID:26160521 PMID:26456670 PMID:30017638 PMID:34843883 PMID:35817128 More...
|
|
NCBI chr 5:90,942,393...90,950,926
Ensembl chr 5:90,942,393...90,950,926
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
increases expression |
ISO |
Poly I-C results in increased expression of CXCL2 mRNA |
CTD |
PMID:23939143 |
|
NCBI chr 5:91,051,758...91,053,797
Ensembl chr 5:91,051,730...91,053,797
|
|
G |
Cxcl3 |
C-X-C motif chemokine ligand 3 |
multiple interactions increases expression |
EXP |
Ethanol inhibits the reaction [Poly I-C results in increased expression of CXCL1 protein] |
CTD |
PMID:19500611 |
|
NCBI chr 5:90,933,960...90,935,952
Ensembl chr 5:90,933,962...90,937,459
|
|
G |
Cxcl9 |
C-X-C motif chemokine ligand 9 |
multiple interactions increases expression increases secretion |
EXP |
Luteolin inhibits the reaction [Poly I-C results in increased expression of CXCL9 mRNA]; methyldithiocarbamate inhibits the reaction [Poly I-C results in increased secretion of CXCL9 protein] |
CTD |
PMID:19426678 PMID:24056979 |
|
NCBI chr 5:92,469,190...92,475,938
Ensembl chr 5:92,469,206...92,475,938
|
|
G |
Cyfip2 |
cytoplasmic FMR1 interacting protein 2 |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of CYFIP2 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr11:46,084,676...46,203,686
Ensembl chr11:46,084,677...46,203,686
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions |
ISO |
Poly I-C promotes the reaction [6-formylindolo(3,2-b)carbazole results in increased expression of CYP1A1 mRNA] |
CTD |
PMID:27783115 |
|
NCBI chr 9:57,595,211...57,611,107
Ensembl chr 9:57,595,211...57,611,107
|
|
G |
Cyp2c29 |
cytochrome P450, family 2, subfamily c, polypeptide 29 |
decreases expression |
ISO |
Poly I-C results in decreased expression of CYP2C6V1 mRNA |
CTD |
PMID:23939143 |
|
NCBI chr19:39,275,541...39,319,157
Ensembl chr19:39,257,849...39,319,157
|
|
G |
Cyp2c52-ps |
cytochrome P450, family 2, subfamily c, polypeptide 52, pseudogene |
decreases expression |
ISO |
Poly I-C results in decreased expression of CYP2C11 mRNA |
CTD |
PMID:23939143 |
|
NCBI chr19:38,965,106...38,992,071
Ensembl chr19:38,965,091...38,991,733
|
|
G |
Cyria |
CYFIP related Rac1 interactor A |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of CYRIA mRNA |
CTD |
PMID:26923065 |
|
NCBI chr12:12,312,136...12,430,966
Ensembl chr12:12,312,140...12,430,966
|
|
G |
Cysrt1 |
cysteine rich tail 1 |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in increased expression of CYSRT1 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 2:25,128,831...25,129,876
Ensembl chr 2:25,128,830...25,132,464
|
|
G |
Dab1 |
disabled 1 |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of DAB1 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 4:103,476,425...104,602,041
Ensembl chr 4:103,476,556...104,602,041
|
|
G |
Dck |
deoxycytidine kinase |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of DCK mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 5:88,912,872...88,931,136
Ensembl chr 5:88,912,855...88,931,140
|
|
G |
Dcun1d3 |
defective in cullin neddylation 1 domain containing 3 |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of DCUN1D3 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 7:119,452,381...119,495,553
Ensembl chr 7:119,452,019...119,495,521
|
|
G |
Dcun1d4 |
defective in cullin neddylation 1 domain containing 4 |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of DCUN1D4 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 5:73,638,353...73,718,137
Ensembl chr 5:73,638,343...73,718,137
|
|
G |
Ddx3x |
DEAD box helicase 3, X-linked |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of DDX3X mRNA |
CTD |
PMID:26923065 |
|
NCBI chr X:13,147,261...13,160,222
Ensembl chr X:13,147,209...13,160,291
|
|
G |
Defb4 |
defensin beta 4 |
increases secretion |
ISO |
Poly I-C results in increased secretion of DEFB4 protein |
CTD |
PMID:17669408 |
|
NCBI chr 8:19,248,720...19,251,563
Ensembl chr 8:19,248,722...19,251,561
|
|
G |
Dlg1 |
discs large MAGUK scaffold protein 1 |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of DLG1 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr16:31,482,261...31,692,174
Ensembl chr16:31,482,261...31,693,947
|
|
G |
Dnm2 |
dynamin 2 |
multiple interactions |
EXP |
DNM2 protein promotes the reaction [Poly I-C results in increased phosphorylation of IRF3 protein] |
CTD |
PMID:25780039 |
|
NCBI chr 9:21,336,167...21,419,055
Ensembl chr 9:21,336,204...21,419,055
|
|
G |
Dnmt1 |
DNA methyltransferase 1 |
multiple interactions |
ISO |
[Arsenicals co-treated with Poly I-C co-treated with Alitretinoin] results in increased expression of DNMT1 mRNA; [Arsenicals co-treated with Poly I-C] results in increased expression of DNMT1 mRNA |
CTD |
PMID:34303791 |
|
NCBI chr 9:20,818,501...20,871,084
Ensembl chr 9:20,818,505...20,871,184
|
|
G |
Dnmt3a |
DNA methyltransferase 3A |
multiple interactions |
ISO |
[Arsenicals co-treated with Poly I-C co-treated with Alitretinoin] results in increased expression of DNMT3A mRNA; [Arsenicals co-treated with Poly I-C] results in increased expression of DNMT3A mRNA |
CTD |
PMID:34303791 |
|
NCBI chr12:3,851,559...3,964,442
Ensembl chr12:3,856,007...3,964,443
|
|
G |
Eea1 |
early endosome antigen 1 |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of EEA1 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr10:95,776,525...95,881,380
Ensembl chr10:95,776,512...95,881,380
|
|
G |
Egr1 |
early growth response 1 |
multiple interactions affects methylation |
EXP ISO |
[Poly I-C results in increased susceptibility to 4-iodo-2,5-dimethoxyphenylisopropylamine] which results in increased expression of EGR1 mRNA; Poly I-C promotes the reaction [4-iodo-2,5-dimethoxyphenylisopropylamine results in increased expression of EGR1 mRNA] Poly I-C affects the methylation of EGR1 promoter |
CTD |
PMID:24889602 PMID:32843831 |
|
NCBI chr18:34,994,260...34,998,009
Ensembl chr18:34,992,876...34,998,037
|
|
G |
Eif2ak2 |
eukaryotic translation initiation factor 2-alpha kinase 2 |
increases expression increases response to substance increases phosphorylation |
ISO EXP |
Poly I-C results in increased expression of EIF2AK2 mRNA EIF2AK2 results in increased susceptibility to Poly I-C Poly I-C results in increased phosphorylation of EIF2AK2 protein |
CTD |
PMID:10944112 PMID:17669408 PMID:22240577 PMID:22558189 |
|
NCBI chr17:79,157,933...79,190,001
Ensembl chr17:79,159,993...79,190,002
|
|
G |
Eif2s1 |
eukaryotic translation initiation factor 2, subunit 1 alpha |
increases phosphorylation |
ISO |
Poly I-C results in increased phosphorylation of EIF2S1 protein |
CTD |
PMID:22240577 |
|
NCBI chr12:78,908,846...78,933,784
Ensembl chr12:78,908,593...78,933,784
|
|
G |
F11r |
F11 receptor |
multiple interactions decreases expression |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Poly I-C results in decreased expression of F11R protein]; CpG ODN 2006 inhibits the reaction [Poly I-C results in decreased expression of F11R protein]; N-(3,5-bis(trifluoromethyl)phenyl)-5-chloro-2-hydroxybenzamide inhibits the reaction [Poly I-C results in decreased expression of F11R protein]; RTKI cpd inhibits the reaction [Poly I-C results in decreased expression of F11R protein]; SB 203580 inhibits the reaction [Poly I-C results in decreased expression of F11R protein] |
CTD |
PMID:20932985 |
|
NCBI chr 1:171,265,129...171,292,161
Ensembl chr 1:171,265,103...171,292,171
|
|
G |
Fabp4 |
fatty acid binding protein 4, adipocyte |
increases expression |
EXP |
Poly I-C results in increased expression of FABP4 mRNA |
CTD |
PMID:15705927 |
|
NCBI chr 3:10,269,406...10,273,653
Ensembl chr 3:10,269,148...10,273,636
|
|
G |
Fam107a |
family with sequence similarity 107, member A |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of FAM107A mRNA |
CTD |
PMID:26923065 |
|
NCBI chr14:14,152,166...14,173,503
Ensembl chr14:14,151,750...14,173,499
|
|
G |
Fmr1 |
fragile X messenger ribonucleoprotein 1 |
multiple interactions decreases expression |
EXP |
Suramin inhibits the reaction [Poly I-C results in decreased expression of FMR1 protein] |
CTD |
PMID:23516405 |
|
NCBI chr X:67,722,144...67,761,569
Ensembl chr X:67,722,147...67,761,569
|
|
G |
Fxyd3 |
FXYD domain-containing ion transport regulator 3 |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in increased expression of FXYD3 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 7:30,769,960...30,776,122
Ensembl chr 7:30,767,597...30,776,129
|
|
G |
Fyttd1 |
forty-two-three domain containing 1 |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of FYTTD1 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr16:32,697,762...32,729,333
Ensembl chr16:32,697,870...32,729,245
|
|
G |
G3bp1 |
G3BP stress granule assembly factor 1 |
affects localization |
ISO |
Poly I-C affects the localization of G3BP1 protein |
CTD |
PMID:22240577 |
|
NCBI chr11:55,360,521...55,391,722
Ensembl chr11:55,360,511...55,395,664
|
|
G |
G3bp2 |
G3BP stress granule assembly factor 2 |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of G3BP2 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 5:92,200,004...92,285,584
Ensembl chr 5:92,200,005...92,231,578
|
|
G |
Gabra1 |
gamma-aminobutyric acid type A receptor subunit alpha 1 |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of GABRA1 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr11:42,021,766...42,073,893
Ensembl chr11:42,021,766...42,073,757
|
|
G |
Gabrb2 |
gamma-aminobutyric acid type A receptor subunit beta 2 |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of GABRB2 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr11:42,310,342...42,523,418
Ensembl chr11:42,310,584...42,519,855
|
|
G |
Gabrg2 |
gamma-aminobutyric acid type A receptor, subunit gamma 2 |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of GABRG2 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr11:41,801,017...41,891,684
Ensembl chr11:41,801,030...41,891,684
|
|
G |
Gad1 |
glutamate decarboxylase 1 |
multiple interactions decreases expression |
ISO |
Cannabidiol inhibits the reaction [Poly I-C results in decreased expression of GAD1 protein] |
CTD |
PMID:31202911 |
|
NCBI chr 2:70,392,109...70,432,358
Ensembl chr 2:70,383,416...70,432,358
|
|
G |
Gdap1 |
ganglioside-induced differentiation-associated-protein 1 |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of GDAP1 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 1:17,202,028...17,234,513
Ensembl chr 1:17,215,586...17,234,495
|
|
G |
Gdi1 |
GDP dissociation inhibitor 1 |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of GDI1 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr X:73,348,618...73,355,473
Ensembl chr X:73,348,604...73,355,468
|
|
G |
Get3 |
guided entry of tail-anchored proteins factor 3, ATPase |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in increased expression of GET3 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 8:85,744,558...85,751,916
Ensembl chr 8:85,744,560...85,751,910
|
|
G |
Gfap |
glial fibrillary acidic protein |
increases expression |
ISO |
Poly I-C results in increased expression of GFAP mRNA |
CTD |
PMID:27317300 |
|
NCBI chr11:102,778,162...102,791,368
Ensembl chr11:102,778,162...102,791,738
|
|
G |
Gh |
growth hormone |
decreases expression |
EXP |
Poly I-C results in decreased expression of GH protein |
CTD |
PMID:21195166 |
|
NCBI chr11:106,191,087...106,194,529
Ensembl chr11:106,191,097...106,192,691
|
|
G |
Glce |
glucuronyl C5-epimerase |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of GLCE mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 9:61,964,526...62,029,891
Ensembl chr 9:61,964,530...62,029,937
|
|
G |
Glrb |
glycine receptor, beta subunit |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of GLRB mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 3:80,750,905...80,820,994
Ensembl chr 3:80,750,906...80,820,967
|
|
G |
Glyr1 |
glyoxylate reductase 1 homolog (Arabidopsis) |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of GLYR1 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr16:4,831,766...4,867,780
Ensembl chr16:4,831,773...4,867,727
|
|
G |
Gmfb |
glia maturation factor, beta |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of GMFB mRNA |
CTD |
PMID:26923065 |
|
NCBI chr14:47,045,606...47,059,711
Ensembl chr14:47,045,606...47,059,699
|
|
G |
Gmppb |
GDP-mannose pyrophosphorylase B |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in increased expression of GMPPB mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 9:107,926,490...107,929,119
Ensembl chr 9:107,926,441...107,930,000
|
|
G |
Gpatch2l |
G patch domain containing 2 like |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of GPATCH2L mRNA |
CTD |
PMID:26923065 |
|
NCBI chr12:86,288,569...86,341,439
Ensembl chr12:86,288,632...86,338,558
|
|
G |
Gpbp1 |
GC-rich promoter binding protein 1 |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of GPBP1 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr13:111,562,214...111,626,658
Ensembl chr13:111,562,214...111,626,645
|
|
G |
Gsr |
glutathione reductase |
decreases expression |
ISO |
Poly I-C results in decreased expression of GSR mRNA |
CTD |
PMID:23939143 |
|
NCBI chr 8:34,143,266...34,188,190
Ensembl chr 8:34,142,551...34,188,191
|
|
G |
Gzmb |
granzyme B |
multiple interactions increases expression |
ISO |
Particulate Matter inhibits the reaction [Poly I-C results in increased expression of GZMB mRNA]; Particulate Matter inhibits the reaction [Poly I-C results in increased expression of GZMB protein]; Vehicle Emissions inhibits the reaction [Poly I-C results in increased expression of GZMB mRNA]; Vehicle Emissions inhibits the reaction [Poly I-C results in increased expression of GZMB protein] Poly I-C results in increased expression of GZMB mRNA; Poly I-C results in increased expression of GZMB protein |
CTD |
PMID:23618096 |
|
NCBI chr14:56,496,293...56,499,791
Ensembl chr14:56,496,295...56,499,717
|
|
G |
Hey2 |
hairy/enhancer-of-split related with YRPW motif 2 |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of HEY2 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr10:30,708,355...30,718,779
Ensembl chr10:30,708,355...30,718,797
|
|
G |
Hmgb1 |
high mobility group box 1 |
multiple interactions |
ISO |
Indoprofen inhibits the reaction [Poly I-C results in increased secretion of and affects the localization of HMGB1 protein]; Poly I-C results in increased secretion of and affects the localization of HMGB1 protein |
CTD |
PMID:34755645 |
|
NCBI chr 5:148,983,512...148,989,867
Ensembl chr 5:148,983,512...149,121,299
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions increases expression |
ISO |
Diclofenac promotes the reaction [Poly I-C results in increased expression of HMOX1 mRNA] |
CTD |
PMID:23939143 |
|
NCBI chr 8:75,820,246...75,827,221
Ensembl chr 8:75,820,249...75,827,217
|
|
G |
Hsp90aa1 |
heat shock protein 90, alpha (cytosolic), class A member 1 |
increases expression |
ISO |
Poly I-C results in increased expression of HSP90AA1 mRNA |
CTD |
PMID:23939143 |
|
NCBI chr12:110,657,470...110,662,829
Ensembl chr12:110,657,039...110,669,162
|
|
G |
Hspa1a |
heat shock protein 1A |
increases expression |
ISO |
Poly I-C results in increased expression of HSPA1A mRNA |
CTD |
PMID:23939143 |
|
NCBI chr17:35,188,335...35,191,132
Ensembl chr17:35,188,166...35,191,132
|
|
G |
Hspa8 |
heat shock protein 8 |
increases expression |
ISO |
Poly I-C results in increased expression of HSPA8 mRNA |
CTD |
PMID:23939143 |
|
NCBI chr 9:40,712,572...40,716,498
Ensembl chr 9:40,712,280...40,721,383
|
|
G |
Htr2a |
5-hydroxytryptamine (serotonin) receptor 2A |
increases expression |
EXP |
Poly I-C results in increased expression of HTR2A mRNA |
CTD |
PMID:24889602 |
|
NCBI chr14:74,878,314...74,944,299
Ensembl chr14:74,878,280...74,946,934
|
|
G |
Ibtk |
inhibitor of Bruton agammaglobulinemia tyrosine kinase |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of IBTK mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 9:85,569,412...85,632,756
Ensembl chr 9:85,569,413...85,631,387
|
|
G |
Ido1 |
indoleamine 2,3-dioxygenase 1 |
increases expression multiple interactions |
ISO |
Poly I-C results in increased expression of IDO1 mRNA poly(I:C) co-treated with tryptophan or alone increases activity and expression of IDO1 protein in Langerhans cell-like dendritic cells |
CTD RGD |
PMID:27783115 PMID:26198597 |
RGD:11528429 |
NCBI chr 8:25,074,148...25,086,987
Ensembl chr 8:25,074,152...25,087,025
|
|
G |
Ido2 |
indoleamine 2,3-dioxygenase 2 |
increases expression |
ISO |
Poly I-C results in increased expression of IDO2 mRNA |
CTD |
PMID:27783115 |
|
NCBI chr 8:25,021,908...25,066,430
Ensembl chr 8:25,021,908...25,066,349
|
|
G |
Ifih1 |
interferon induced with helicase C domain 1 |
multiple interactions increases expression |
ISO |
IRF7 protein mutant form inhibits the reaction [Poly I-C results in increased expression of IFIH1 mRNA]; Nicotine inhibits the reaction [Poly I-C results in increased expression of IFIH1 mRNA] |
CTD |
PMID:30341573 PMID:31154625 |
|
NCBI chr 2:62,426,137...62,476,599
Ensembl chr 2:62,426,142...62,476,599
|
|
G |
Ifit1bl1 |
interferon induced protein with tetratricpeptide repeats 1B like 1 |
increases expression multiple interactions |
ISO |
Poly I-C results in increased expression of IFIT1 mRNA IRF7 protein mutant form inhibits the reaction [Poly I-C results in increased expression of IFIT1 mRNA]; Nicotine inhibits the reaction [Poly I-C results in increased expression of IFIT1 mRNA] |
CTD |
PMID:31154625 |
|
NCBI chr19:34,570,288...34,640,382
Ensembl chr19:34,570,291...34,579,356
|
|
G |
Ifit2 |
interferon-induced protein with tetratricopeptide repeats 2 |
increases expression multiple interactions |
ISO |
Poly I-C results in increased expression of IFIT2 mRNA Acetylcysteine inhibits the reaction [Dieldrin inhibits the reaction [Poly I-C results in increased expression of IFIT2 mRNA]]; Dieldrin inhibits the reaction [Poly I-C results in increased expression of IFIT2 mRNA] |
CTD |
PMID:34051100 |
|
NCBI chr19:34,527,961...34,553,934
Ensembl chr19:34,528,094...34,553,819
|
|
G |
Ifitm1 |
interferon induced transmembrane protein 1 |
increases expression |
ISO |
Poly I-C results in increased expression of IFITM1 mRNA |
CTD |
PMID:22240577 |
|
NCBI chr 7:140,547,342...140,549,740
Ensembl chr 7:140,547,134...140,549,738
|
|
G |
Ifna1 |
interferon alpha 1 |
increases expression |
ISO |
Poly I-C results in increased expression of IFNA1 mRNA |
CTD |
PMID:28726298 |
|
NCBI chr 4:88,768,324...88,768,893
Ensembl chr 4:88,768,324...88,768,893
|
|
G |
Ifnb1 |
interferon beta 1, fibroblast |
increases expression increases secretion multiple interactions |
ISO EXP |
Poly I-C results in increased expression of IFNB1 mRNA; Poly I-C results in increased expression of IFNB1 protein Poly I-C results in increased secretion of IFNB1 protein [Dronabinol co-treated with Cannabidiol] inhibits the reaction [Poly I-C results in increased expression of IFNB1 mRNA]; [Vehicle Emissions analog co-treated with Poly I-C] results in increased expression of IFNB1 mRNA; Cannabidiol inhibits the reaction [Poly I-C results in increased expression of IFNB1 mRNA]; Dronabinol inhibits the reaction [Poly I-C results in increased expression of IFNB1 mRNA]; IRF7 protein affects the reaction [Poly I-C results in increased expression of IFNB1 mRNA]; IRF7 protein mutant form affects the reaction [Nicotine inhibits the reaction [Poly I-C results in increased expression of IFNB1 mRNA]]; IRF7 protein mutant form inhibits the reaction [Nicotine inhibits the reaction [Poly I-C results in increased secretion of IFNB1 protein]]; IRF7 protein mutant form inhibits the reaction [Poly I-C results in increased secretion of IFNB1 protein]; Nicotine inhibits the reaction [Poly I-C results in increased expression of IFNB1 mRNA]; Nicotine inhibits the reaction [Poly I-C results in increased secretion of IFNB1 protein]; Smoke inhibits the reaction [Poly I-C results in increased expression of IFNB1 mRNA]; TLR3 protein affects the reaction [Poly I-C results in increased expression of IFNB1 mRNA]; TP53 protein affects the reaction [Poly I-C results in increased expression of IFNB1 mRNA]; Wortmannin inhibits the reaction [[Vehicle Emissions analog co-treated with Poly I-C] results in increased expression of IFNB1 mRNA] apilimod inhibits the reaction [Poly I-C results in increased secretion of IFNB1 protein]; APPL1 protein promotes the reaction [Poly I-C results in increased expression of IFNB1 mRNA]; BX795 inhibits the reaction [Poly I-C results in increased expression of IFNB1 protein]; Luteolin inhibits the reaction [Poly I-C results in increased expression of IFNB1 mRNA]; pitavastatin inhibits the reaction [Poly I-C results in increased expression of IFNB1 mRNA]; Pravastatin inhibits the reaction [Poly I-C results in increased expression of IFNB1 mRNA]; Progesterone inhibits the reaction [Poly I-C results in increased expression of IFNB1 mRNA]; Resveratrol inhibits the reaction [Poly I-C results in increased expression of IFNB1 mRNA]; sodium arsenite inhibits the reaction [Poly I-C results in increased expression of IFNB1 mRNA]; sodium arsenite inhibits the reaction [Poly I-C results in increased secretion of IFNB1 protein]; Sodium Selenite inhibits the reaction [Poly I-C results in increased expression of IFNB1 mRNA]; trametinib promotes the reaction [Poly I-C results in increased expression of IFNB1 mRNA] MIR26A mRNA inhibits the reaction [Poly I-C results in increased expression of IFNB1 mRNA] |
CTD |
PMID:16116226 PMID:16399790 PMID:17669408 PMID:18279804 PMID:18323514 PMID:18779317 PMID:19426678 PMID:21418039 PMID:22546503 PMID:22558189 PMID:24423102 PMID:24600036 PMID:25780039 PMID:28572013 PMID:28726298 PMID:30726814 PMID:31154625 PMID:32244040 PMID:35817128 PMID:36958387 More...
|
|
NCBI chr 4:88,440,253...88,441,083
Ensembl chr 4:88,440,262...88,441,011
|
|
G |
Ifng |
interferon gamma |
multiple interactions increases expression increases secretion |
ISO EXP |
[Poly I-C co-treated with IFNG protein] results in increased secretion of CD40 protein; [Poly I-C co-treated with IFNG protein] results in increased secretion of CD86 protein; Smoke inhibits the reaction [Poly I-C results in increased expression of IFNG mRNA] Ethanol inhibits the reaction [Poly I-C results in increased expression of IFNG protein] Poly I-C results in increased expression of IFNG mRNA; Poly I-C results in increased expression of IFNG protein Poly I-C results in increased secretion of IFNG protein |
CTD |
PMID:9328138 PMID:16224278 PMID:17321468 PMID:19500611 PMID:23618096 PMID:23939143 PMID:28572013 PMID:30836164 More...
|
|
NCBI chr10:118,276,951...118,281,799
Ensembl chr10:118,276,951...118,281,797
|
|
G |
Igf1 |
insulin-like growth factor 1 |
multiple interactions decreases expression |
EXP |
IL6 protein affects the reaction [Poly I-C results in decreased expression of IGF1 protein] Poly I-C results in decreased expression of IGF1 mRNA; Poly I-C results in decreased expression of IGF1 protein |
CTD |
PMID:1705203 PMID:21195166 |
|
NCBI chr10:87,694,127...87,772,909
Ensembl chr10:87,694,127...87,772,904
|
|
G |
Igfbp3 |
insulin-like growth factor binding protein 3 |
multiple interactions decreases expression |
EXP |
IL6 protein affects the reaction [Poly I-C results in decreased expression of IGFBP3 protein] |
CTD |
PMID:21195166 |
|
NCBI chr11:7,156,086...7,165,498
Ensembl chr11:7,156,086...7,163,923
|
|
G |
Igsf6 |
immunoglobulin superfamily, member 6 |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in increased expression of IGSF6 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 7:120,663,290...120,673,753
Ensembl chr 7:120,663,290...120,673,795
|
|
G |
Ikbke |
inhibitor of kappaB kinase epsilon |
multiple interactions increases phosphorylation |
EXP |
APPL1 protein promotes the reaction [Poly I-C results in increased phosphorylation of IKBKE protein] |
CTD |
PMID:25780039 |
|
NCBI chr 1:131,182,337...131,207,339
Ensembl chr 1:131,182,080...131,207,344
|
|
G |
Il10 |
interleukin 10 |
multiple interactions increases secretion increases expression |
ISO EXP |
CEP-11004 inhibits the reaction [Poly I-C results in increased secretion of IL10 protein]; SB 203580 inhibits the reaction [Poly I-C results in increased secretion of IL10 protein] Citrinin inhibits the reaction [Poly I-C results in increased expression of IL10 mRNA]; Citrinin inhibits the reaction [Poly I-C results in increased expression of IL10 protein] Poly I-C results in increased expression of IL10 mRNA; Poly I-C results in increased expression of IL10 protein |
CTD |
PMID:16224278 PMID:17698565 PMID:22771370 PMID:23618096 PMID:23939143 PMID:30836164 More...
|
|
NCBI chr 1:130,947,459...130,952,707
Ensembl chr 1:130,947,582...130,952,711
|
|
G |
Il12a |
interleukin 12a |
multiple interactions increases expression |
ISO |
6-formylindolo(3,2-b)carbazole inhibits the reaction [Poly I-C results in increased expression of IL12A mRNA]; indole-3-carbinol inhibits the reaction [Poly I-C results in increased expression of IL12A mRNA]; Tetrachlorodibenzodioxin inhibits the reaction [Poly I-C results in increased expression of IL12A mRNA] |
CTD |
PMID:27783115 |
|
NCBI chr 3:68,597,977...68,605,881
Ensembl chr 3:68,597,977...68,605,880
|
|
G |
Il12b |
interleukin 12b |
multiple interactions increases expression |
ISO EXP |
[[Poly I-C binds to and results in increased activity of TLR3 protein] which co-treated with Nanotubes, Carbon] results in increased secretion of IL12B protein; Particulate Matter analog inhibits the reaction [Poly I-C results in increased expression of IL12B protein]; Vehicle Emissions analog inhibits the reaction [Poly I-C results in increased expression of IL12B protein] Ethanol inhibits the reaction [Poly I-C results in increased expression of IL12B protein]; Luteolin inhibits the reaction [Poly I-C results in increased expression of IL12B mRNA] Poly I-C results in increased expression of IL12B mRNA; Poly I-C results in increased expression of IL12B protein |
CTD |
PMID:16890772 PMID:19426678 PMID:19500611 PMID:23266719 |
|
NCBI chr11:44,290,890...44,305,504
Ensembl chr11:44,290,890...44,304,860
|
|
G |
Il17a |
interleukin 17A |
increases expression |
EXP |
Poly I-C results in increased expression of IL17A protein |
CTD |
PMID:30836164 |
|
NCBI chr 1:20,801,129...20,804,720
Ensembl chr 1:20,801,129...20,804,720
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions increases expression increases secretion |
EXP ISO |
APPL1 protein inhibits the reaction [Poly I-C results in increased expression of IL1B protein]; Citrinin inhibits the reaction [Poly I-C results in increased expression of IL1B mRNA]; Ethanol inhibits the reaction [Poly I-C results in increased expression of IL1B protein]; Poly I-C promotes the reaction [deoxynivalenol results in increased expression of IL1B mRNA] Poly I-C results in increased expression of IL1B mRNA; Poly I-C results in increased expression of IL1B protein 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane promotes the reaction [Poly I-C results in increased expression of IL1B protein]; 4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol promotes the reaction [Poly I-C results in increased expression of IL1B protein]; 6-formylindolo(3,2-b)carbazole promotes the reaction [Poly I-C results in increased expression of IL1B mRNA]; Estradiol promotes the reaction [Poly I-C results in increased expression of IL1B protein]; Tetrachlorodibenzodioxin promotes the reaction [Poly I-C results in increased expression of IL1B mRNA] Poly I-C results in increased secretion of IL1B protein |
CTD |
PMID:16687389 PMID:17321468 PMID:19500611 PMID:22771370 PMID:23618096 PMID:23939143 PMID:25780039 PMID:27783115 PMID:28316773 PMID:30017638 More...
|
|
NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059
|
|
G |
Il2 |
interleukin 2 |
increases expression increases secretion |
EXP ISO |
Poly I-C results in increased expression of IL2 mRNA Poly I-C results in increased secretion of IL2 protein |
CTD |
PMID:9328138 PMID:23618096 |
|
NCBI chr 3:37,174,862...37,180,103
Ensembl chr 3:37,174,672...37,180,108
|
|
G |
Il27 |
interleukin 27 |
increases expression multiple interactions |
EXP |
Poly I-C results in increased expression of IL27 mRNA Luteolin inhibits the reaction [Poly I-C results in increased expression of IL27 mRNA] |
CTD |
PMID:19426678 |
|
NCBI chr 7:126,188,181...126,194,197
Ensembl chr 7:126,188,182...126,194,113
|
|
G |
Il33 |
interleukin 33 |
multiple interactions increases expression |
ISO EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane promotes the reaction [Poly I-C results in increased expression of IL33 protein]; 4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol promotes the reaction [Poly I-C results in increased expression of IL33 protein]; Estradiol promotes the reaction [Poly I-C results in increased expression of IL33 protein] N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [Poly I-C results in increased expression of IL33 protein] |
CTD |
PMID:25747661 PMID:30017638 |
|
NCBI chr19:29,902,513...29,938,118
Ensembl chr19:29,902,514...29,938,118
|
|
G |
Il4 |
interleukin 4 |
multiple interactions increases response to substance increases secretion increases expression |
ISO EXP |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased degradation of NFKBIA protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CCL5 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CXCL8 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]; 4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol promotes the reaction [Poly I-C results in increased expression of IL4 protein]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of Prostaglandin D2]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of Prostaglandin D2]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [Itraconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [Itraconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of Prostaglandin D2]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [Itraconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [Itraconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [Ketoconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [Ketoconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of Prostaglandin D2]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [Ketoconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [Ketoconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [luliconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [luliconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of Prostaglandin D2]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [luliconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [luliconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [Terbinafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [Terbinafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of Prostaglandin D2]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [Terbinafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [Terbinafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]]; [Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2; [Poly I-C co-treated with IL4 protein] results in decreased secretion of Prostaglandin D2; [Poly I-C co-treated with IL4 protein] results in increased degradation of NFKBIA protein; [Poly I-C co-treated with IL4 protein] results in increased expression of CCL5 mRNA; [Poly I-C co-treated with IL4 protein] results in increased expression of CXCL8 mRNA; [Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA; [Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein; [Poly I-C co-treated with IL4 protein] results in increased secretion of Dinoprost; [Poly I-C co-treated with IL4 protein] results in increased secretion of Dinoprostone; [Poly I-C co-treated with IL4 protein] results in increased secretion of Thromboxane B2; amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]; amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of Prostaglandin D2]; amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased degradation of NFKBIA protein]; amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CCL5 mRNA]; amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CXCL8 mRNA]; amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]; amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]; amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased secretion of Thromboxane B2]; amorolfine promotes the reaction [[Poly I-C co-treated with IL4 protein] results in increased secretion of Dinoprostone]; butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]; butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of Prostaglandin D2]; butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased degradation of NFKBIA protein]; butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CCL5 mRNA]; butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CXCL8 mRNA]; butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]; butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]; butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased secretion of Thromboxane B2]; butenafine promotes the reaction [[Poly I-C co-treated with IL4 protein] results in increased secretion of Dinoprostone]; Estradiol promotes the reaction [Poly I-C results in increased expression of IL4 protein]; helenalin inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CCL5 mRNA]; helenalin inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CXCL8 mRNA]; helenalin inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]; helenalin inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]; IL4 protein promotes the reaction [Poly I-C results in increased expression of CCL5 mRNA]; IL4 protein promotes the reaction [Poly I-C results in increased expression of CXCL8 mRNA]; IL4 protein promotes the reaction [Poly I-C results in increased expression of TSLP mRNA]; IL4 protein promotes the reaction [Poly I-C results in increased expression of TSLP protein]; Itraconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]; Itraconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of Prostaglandin D2]; Itraconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased degradation of NFKBIA protein]; Itraconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CCL5 mRNA]; Itraconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CXCL8 mRNA]; Itraconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]; Itraconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]; Itraconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased secretion of Thromboxane B2]; Itraconazole promotes the reaction [[Poly I-C co-treated with IL4 protein] results in increased secretion of Dinoprostone]; Ketoconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]; Ketoconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of Prostaglandin D2]; Ketoconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased degradation of NFKBIA protein]; Ketoconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CCL5 mRNA]; Ketoconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CXCL8 mRNA]; Ketoconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]; Ketoconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]; Ketoconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased secretion of Thromboxane B2]; Ketoconazole promotes the reaction [[Poly I-C co-treated with IL4 protein] results in increased secretion of Dinoprostone]; luliconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]; luliconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of Prostaglandin D2]; luliconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased degradation of NFKBIA protein]; luliconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CCL5 mRNA]; luliconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CXCL8 mRNA]; luliconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]; luliconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]; luliconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased secretion of Thromboxane B2]; luliconazole promotes the reaction [[Poly I-C co-treated with IL4 protein] results in increased secretion of Dinoprostone]; Particulate Matter inhibits the reaction [Poly I-C results in increased secretion of IL4 protein]; Terbinafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]; Terbinafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of Prostaglandin D2]; Terbinafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased degradation of NFKBIA protein]; Terbinafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CCL5 mRNA]; Terbinafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CXCL8 mRNA]; Terbinafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]; Terbinafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]; Terbinafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased secretion of Thromboxane B2]; Terbinafine promotes the reaction [[Poly I-C co-treated with IL4 protein] results in increased secretion of Dinoprostone]; Vehicle Emissions inhibits the reaction [Poly I-C results in increased secretion of IL4 protein] IL4 protein results in increased susceptibility to Poly I-C |
CTD |
PMID:23618096 PMID:23688403 PMID:30017638 PMID:30836164 PMID:34740670 |
|
NCBI chr11:53,503,287...53,509,492
Ensembl chr11:53,493,809...53,509,496
|
|
G |
Il6 |
interleukin 6 |
multiple interactions increases expression increases secretion |
ISO EXP |
[Vehicle Emissions analog co-treated with Poly I-C] results in increased secretion of IL6 protein; CEP-11004 inhibits the reaction [Poly I-C results in increased secretion of IL6 protein]; Particulate Matter promotes the reaction [Poly I-C results in increased expression of IL6]; SB 203580 inhibits the reaction [Poly I-C results in increased secretion of IL6 protein]; Smoke inhibits the reaction [Poly I-C results in increased secretion of IL6 protein]; TLR3 mRNA promotes the reaction [Poly I-C results in increased expression of IL6 mRNA]; TRAF6 mutant form inhibits the reaction [Vehicle Emissions analog promotes the reaction [Poly I-C results in increased expression of IL6 mRNA]]; Vehicle Emissions analog promotes the reaction [Poly I-C results in increased expression of IL6 mRNA]; Vehicle Emissions promotes the reaction [Poly I-C results in increased expression of IL6] Poly I-C results in increased expression of IL6; Poly I-C results in increased expression of IL6 mRNA Ethanol inhibits the reaction [Poly I-C results in increased expression of IL6 protein]; IL6 protein affects the reaction [Poly I-C results in decreased expression of IGF1 protein]; IL6 protein affects the reaction [Poly I-C results in decreased expression of IGFBP3 protein]; IL6 protein affects the reaction [Poly I-C results in increased expression of PRL2B1 mRNA]; IL6 protein affects the reaction [Poly I-C results in increased phosphorylation of and results in increased activity of STAT3 protein]; Luteolin inhibits the reaction [Poly I-C results in increased expression of IL6 mRNA]; pitavastatin inhibits the reaction [Poly I-C results in increased expression of IL6 mRNA]; Poly I-C promotes the reaction [deoxynivalenol results in increased expression of IL6 mRNA]; Pravastatin inhibits the reaction [Poly I-C results in increased expression of IL6 mRNA]; sodium arsenite inhibits the reaction [Poly I-C results in increased expression of IL6 mRNA] Poly I-C results in increased expression of IL6 mRNA; Poly I-C results in increased expression of IL6 protein |
CTD |
PMID:9328138 PMID:16399790 PMID:16687389 PMID:17698565 PMID:18323514 PMID:19426678 PMID:19500611 PMID:21195166 PMID:23939143 PMID:24709138 PMID:26160521 PMID:28316773 PMID:30341573 PMID:30726814 PMID:30836164 PMID:35817128 PMID:36958387 More...
|
|
NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979
|
|
G |
Irf3 |
interferon regulatory factor 3 |
increases phosphorylation multiple interactions affects localization |
ISO EXP |
Poly I-C results in increased phosphorylation of IRF3 protein [Dronabinol co-treated with Cannabidiol] inhibits the reaction [Poly I-C affects the localization of IRF3 protein]; [Vehicle Emissions analog co-treated with Poly I-C] affects the localization of IRF3 protein; Cannabidiol inhibits the reaction [Poly I-C affects the localization of IRF3 protein]; Dronabinol inhibits the reaction [Poly I-C results in increased localization of IRF3 protein]; TP53 protein affects the reaction [Poly I-C results in increased phosphorylation of IRF3 protein] APPL1 protein promotes the reaction [Poly I-C results in increased phosphorylation of IRF3 protein]; BX795 inhibits the reaction [Poly I-C results in increased phosphorylation of IRF3 protein]; Chloroquine inhibits the reaction [Poly I-C results in increased phosphorylation of IRF3 protein]; chrysin inhibits the reaction [Poly I-C results in increased expression of IRF3 mRNA]; DNM2 protein promotes the reaction [Poly I-C results in increased phosphorylation of IRF3 protein]; eriodictyol inhibits the reaction [Poly I-C results in increased expression of IRF3 mRNA]; Quercetin inhibits the reaction [Poly I-C results in increased expression of IRF3 mRNA]; Sodium Selenite inhibits the reaction [Poly I-C results in increased activity of IRF3 protein] |
CTD |
PMID:16399790 PMID:18279804 PMID:18779317 PMID:19426678 PMID:25780039 PMID:32244040 PMID:36958387 More...
|
|
NCBI chr 7:44,647,072...44,652,272
Ensembl chr 7:44,647,072...44,652,272
|
|
G |
Irf7 |
interferon regulatory factor 7 |
increases expression multiple interactions |
ISO |
Poly I-C results in increased expression of IRF7 mRNA IRF7 protein affects the reaction [Poly I-C results in increased expression of IFNB1 mRNA]; IRF7 protein mutant form affects the reaction [Nicotine inhibits the reaction [Poly I-C results in increased expression of IFNB1 mRNA]]; IRF7 protein mutant form inhibits the reaction [Nicotine inhibits the reaction [Poly I-C results in increased secretion of IFNB1 protein]]; IRF7 protein mutant form inhibits the reaction [Poly I-C results in increased expression of IFIH1 mRNA]; IRF7 protein mutant form inhibits the reaction [Poly I-C results in increased expression of IFIT1 mRNA]; IRF7 protein mutant form inhibits the reaction [Poly I-C results in increased expression of IRF7 mRNA]; IRF7 protein mutant form inhibits the reaction [Poly I-C results in increased expression of IRF9 mRNA]; IRF7 protein mutant form inhibits the reaction [Poly I-C results in increased expression of ISG15 mRNA]; IRF7 protein mutant form inhibits the reaction [Poly I-C results in increased expression of OAS1 mRNA]; IRF7 protein mutant form inhibits the reaction [Poly I-C results in increased expression of RIGI mRNA]; IRF7 protein mutant form inhibits the reaction [Poly I-C results in increased expression of STAT1 mRNA]; IRF7 protein mutant form inhibits the reaction [Poly I-C results in increased expression of STAT2 mRNA]; IRF7 protein mutant form inhibits the reaction [Poly I-C results in increased secretion of IFNB1 protein]; Nicotine inhibits the reaction [Poly I-C results in increased expression of IRF7 mRNA] cyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl ester inhibits the reaction [Poly I-C results in increased expression of IRF7 mRNA] |
CTD |
PMID:22240577 PMID:28726298 PMID:31154625 |
|
NCBI chr 7:140,843,096...140,846,412
Ensembl chr 7:140,842,619...140,846,394
|
|
G |
Irf9 |
interferon regulatory factor 9 |
multiple interactions increases expression |
ISO |
IRF7 protein mutant form inhibits the reaction [Poly I-C results in increased expression of IRF9 mRNA] |
CTD |
PMID:22240577 PMID:31154625 |
|
NCBI chr14:55,841,442...55,847,487
Ensembl chr14:55,841,028...55,847,487
|
|
G |
Isg15 |
ISG15 ubiquitin-like modifier |
multiple interactions increases expression |
ISO EXP |
IRF7 protein mutant form inhibits the reaction [Poly I-C results in increased expression of ISG15 mRNA]; Nicotine inhibits the reaction [Poly I-C results in increased expression of ISG15 mRNA] |
CTD |
PMID:31154625 PMID:36958387 |
|
NCBI chr 4:156,283,881...156,285,275
Ensembl chr 4:156,283,912...156,285,253
|
|
G |
Itgam |
integrin alpha M |
increases expression |
ISO |
Poly I-C results in increased expression of ITGAM mRNA; Poly I-C results in increased expression of ITGAM protein |
CTD |
PMID:27317300 |
|
NCBI chr 7:127,661,812...127,717,663
Ensembl chr 7:127,661,812...127,717,663
|
|
G |
Jcad |
junctional cadherin 5 associated |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of JCAD mRNA |
CTD |
PMID:26923065 |
|
NCBI chr18:4,590,775...4,682,869
Ensembl chr18:4,634,878...4,682,869
|
|
G |
Kcna2 |
potassium voltage-gated channel, shaker-related subfamily, member 2 |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of KCNA2 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 3:106,998,203...107,022,321
Ensembl chr 3:107,008,462...107,022,321
|
|
G |
Kcnip4 |
Kv channel interacting protein 4 |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of KCNIP4 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 5:48,546,845...49,682,464
Ensembl chr 5:48,546,844...49,682,249
|
|
G |
Kcnq5 |
potassium voltage-gated channel, subfamily Q, member 5 |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of KCNQ5 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 1:21,468,623...22,032,874
Ensembl chr 1:21,468,627...22,032,166
|
|
G |
Kif5b |
kinesin family member 5B |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of KIF5B mRNA |
CTD |
PMID:26923065 |
|
NCBI chr18:6,201,005...6,241,524
Ensembl chr18:6,201,002...6,242,174
|
|
G |
Kif5c |
kinesin family member 5C |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of KIF5C mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 2:49,509,298...49,664,790
Ensembl chr 2:49,509,310...49,664,790
|
|
G |
Klf4 |
Kruppel-like transcription factor 4 (gut) |
multiple interactions increases expression |
ISO |
Poly I-C promotes the reaction [MSI1 protein results in increased expression of KLF4 protein] Poly I-C results in increased expression of KLF4 protein |
CTD |
PMID:29486283 |
|
NCBI chr 4:55,527,137...55,536,984
Ensembl chr 4:55,527,143...55,532,466
|
|
G |
Klrk1 |
killer cell lectin-like receptor subfamily K, member 1 |
increases expression |
EXP |
Poly I-C results in increased expression of KLRK1 mRNA; Poly I-C results in increased expression of KLRK1 protein |
CTD |
PMID:16472598 |
|
NCBI chr 6:129,587,286...129,600,863
Ensembl chr 6:129,587,286...129,600,827
|
|
G |
Kpna3 |
karyopherin subunit alpha 3 |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of KPNA3 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr14:61,602,635...61,677,396
Ensembl chr14:61,602,660...61,677,323
|
|
G |
Kpna7 |
karyopherin subunit alpha 7 |
multiple interactions increases expression |
ISO |
Atorvastatin inhibits the reaction [Poly I-C results in increased expression of KPNA7 mRNA]; Ivermectin inhibits the reaction [Poly I-C results in increased expression of KPNA7 mRNA] |
CTD |
PMID:34696514 |
|
NCBI chr 5:144,920,537...144,946,446
Ensembl chr 5:144,920,329...145,020,840
|
|
G |
Lsm14b |
LSM family member 14B |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in increased expression of LSM14B mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 2:179,666,770...179,677,254
Ensembl chr 2:179,666,780...179,677,258
|
|
G |
Mal2 |
mal, T cell differentiation protein 2 |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of MAL2 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr15:54,434,762...54,466,242
Ensembl chr15:54,434,588...54,466,243
|
|
G |
Map3k11 |
mitogen-activated protein kinase kinase kinase 11 |
increases phosphorylation |
ISO |
Poly I-C results in increased phosphorylation of MAP3K11 protein |
CTD |
PMID:17698565 |
|
NCBI chr19:5,738,764...5,752,893
Ensembl chr19:5,738,770...5,752,893
|
|
G |
Mapk1 |
mitogen-activated protein kinase 1 |
decreases phosphorylation multiple interactions increases phosphorylation |
EXP |
Poly I-C results in decreased phosphorylation of MAPK1 protein Suramin inhibits the reaction [Poly I-C results in decreased phosphorylation of MAPK1 protein]; trametinib inhibits the reaction [Poly I-C results in increased phosphorylation of MAPK1 protein]; U 0126 inhibits the reaction [Poly I-C results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:23516405 PMID:25780039 |
|
NCBI chr16:16,801,246...16,865,317
Ensembl chr16:16,801,246...16,865,317
|
|
G |
Mapk3 |
mitogen-activated protein kinase 3 |
decreases phosphorylation multiple interactions increases phosphorylation |
EXP |
Poly I-C results in decreased phosphorylation of MAPK3 protein Suramin inhibits the reaction [Poly I-C results in decreased phosphorylation of MAPK3 protein]; trametinib inhibits the reaction [Poly I-C results in increased phosphorylation of MAPK3 protein]; U 0126 inhibits the reaction [Poly I-C results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:23516405 PMID:25780039 |
|
NCBI chr 7:126,358,798...126,364,988
Ensembl chr 7:126,358,773...126,364,991
|
|
G |
Mapk4 |
mitogen-activated protein kinase 4 |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of MAPK4 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr18:74,061,557...74,198,643
Ensembl chr18:74,061,557...74,198,430
|
|
G |
Mapk9 |
mitogen-activated protein kinase 9 |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of MAPK9 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr11:49,737,558...49,777,248
Ensembl chr11:49,737,578...49,777,248
|
|
G |
Mapre1 |
microtubule-associated protein, RP/EB family, member 1 |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of MAPRE1 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 2:153,583,131...153,615,237
Ensembl chr 2:153,583,194...153,615,230
|
|
G |
Marchf7 |
membrane associated ring-CH-type finger 7 |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of MARCHF7 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 2:60,040,086...60,079,555
Ensembl chr 2:60,040,231...60,081,020
|
|
G |
Mblac2 |
metallo-beta-lactamase domain containing 2 |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of MBLAC2 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr13:81,859,536...81,901,394
Ensembl chr13:81,859,460...81,901,394
|
|
G |
Mbp |
myelin basic protein |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of MBP mRNA |
CTD |
PMID:26923065 |
|
NCBI chr18:82,492,883...82,603,762
Ensembl chr18:82,493,271...82,603,762
|
|
G |
Mef2c |
myocyte enhancer factor 2C |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of MEF2C mRNA |
CTD |
PMID:26923065 |
|
NCBI chr13:83,652,136...83,815,197
Ensembl chr13:83,652,153...83,815,199
|
|
G |
Micos13 |
mitochondrial contact site and cristae organizing system subunit 13 |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in increased expression of MICOS13 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr17:56,914,452...56,916,771
Ensembl chr17:56,914,452...56,916,771
|
|
G |
Micu3 |
mitochondrial calcium uptake family, member 3 |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of MICU3 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 8:40,760,394...40,841,824
Ensembl chr 8:40,760,499...40,839,349
|
|
G |
Mir148b |
microRNA 148b |
multiple interactions |
ISO |
[Arsenicals co-treated with Poly I-C] results in decreased expression of MIR148B mRNA |
CTD |
PMID:34303791 |
|
NCBI chr15:103,193,552...103,193,648
Ensembl chr15:103,193,552...103,193,648
|
|
G |
Mir152 |
microRNA 152 |
multiple interactions |
ISO |
[Arsenicals co-treated with Poly I-C co-treated with Alitretinoin] results in decreased expression of MIR152 mRNA; [Arsenicals co-treated with Poly I-C] results in decreased expression of MIR152 mRNA |
CTD |
PMID:34303791 |
|
NCBI chr11:96,741,219...96,741,291
Ensembl chr11:96,741,219...96,741,291
|
|
G |
Mir155 |
microRNA 155 |
multiple interactions increases expression |
EXP |
MIR155 mRNA inhibits the reaction [Progesterone inhibits the reaction [Poly I-C results in increased expression of MIR155 mRNA]]; Progesterone inhibits the reaction [Poly I-C results in increased expression of MIR155 mRNA] |
CTD |
PMID:22546503 |
|
NCBI chr16:84,511,028...84,511,092
Ensembl chr16:84,511,028...84,511,092
|
|
G |
Mir26a-1 |
microRNA 26a-1 |
multiple interactions |
ISO |
MIR26A mRNA inhibits the reaction [Poly I-C results in increased activity of TLR3 protein]; MIR26A mRNA inhibits the reaction [Poly I-C results in increased expression of IFNB1 mRNA]; MIR26A mRNA inhibits the reaction [Poly I-C results in increased expression of TNF mRNA]; MIR26A mRNA inhibits the reaction [Poly I-C results in increased expression of TNF protein] |
CTD |
PMID:24423102 |
|
NCBI chr 9:118,860,864...118,860,953
Ensembl chr 9:118,860,864...118,860,953
|
|
G |
Mir29c |
microRNA 29c |
multiple interactions |
ISO |
[Arsenicals co-treated with Poly I-C co-treated with Alitretinoin] results in decreased expression of MIR29C mRNA; [Arsenicals co-treated with Poly I-C] results in decreased expression of MIR29C mRNA |
CTD |
PMID:34303791 |
|
NCBI chr 1:194,719,855...194,719,942
Ensembl chr 1:194,719,855...194,719,942
|
|
G |
Mrps15 |
mitochondrial ribosomal protein S15 |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in increased expression of MRPS15 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 4:125,940,721...125,949,329
Ensembl chr 4:125,940,718...125,949,325
|
|
G |
Msi1 |
musashi RNA-binding protein 1 |
multiple interactions |
ISO |
Poly I-C promotes the reaction [MSI1 protein results in increased expression of KLF4 protein]; Poly I-C promotes the reaction [MSI1 protein results in increased expression of MYC protein]; Poly I-C promotes the reaction [MSI1 protein results in increased expression of POU5F1 protein]; Poly I-C promotes the reaction [MSI1 protein results in increased expression of SOX2 protein] |
CTD |
PMID:29486283 |
|
NCBI chr 5:115,567,734...115,593,757
Ensembl chr 5:115,567,658...115,593,757
|
|
G |
Mtpn |
myotrophin |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of MTPN mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 6:35,485,759...35,516,823
Ensembl chr 6:35,485,841...35,516,823
|
|
G |
Mtrex |
Mtr4 exosome RNA helicase |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of MTREX mRNA |
CTD |
PMID:26923065 |
|
NCBI chr13:113,004,306...113,063,914
Ensembl chr13:113,003,952...113,063,932
|
|
G |
Mx1 |
MX dynamin-like GTPase 1 |
increases expression multiple interactions |
ISO |
Poly I-C results in increased expression of MX1 mRNA Acetylcysteine inhibits the reaction [Dieldrin inhibits the reaction [Poly I-C results in increased expression of MX1 mRNA]]; Dieldrin inhibits the reaction [Poly I-C results in increased expression of MX1 mRNA] |
CTD |
PMID:17669408 PMID:22558189 PMID:34051100 |
|
NCBI chr16:97,248,235...97,264,106
Ensembl chr16:97,248,235...97,264,107
|
|
G |
Myc |
myelocytomatosis oncogene |
increases expression multiple interactions |
ISO |
Poly I-C results in increased expression of MYC protein Poly I-C promotes the reaction [MSI1 protein results in increased expression of MYC protein] |
CTD |
PMID:29486283 |
|
NCBI chr15:61,857,190...61,862,210
Ensembl chr15:61,857,240...61,862,223
|
|
G |
Myd88 |
myeloid differentiation primary response gene 88 |
increases expression multiple interactions |
EXP |
Poly I-C results in increased expression of MYD88 mRNA cinnamaldehyde inhibits the reaction [Poly I-C results in increased expression of MYD88 mRNA] |
CTD |
PMID:18306459 |
|
NCBI chr 9:119,165,000...119,169,084
Ensembl chr 9:119,165,000...119,170,477
|
|
G |
Naa60 |
N(alpha)-acetyltransferase 60, NatF catalytic subunit |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of NAA60 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr16:3,690,365...3,722,645
Ensembl chr16:3,690,239...3,722,634
|
|
G |
Napb |
N-ethylmaleimide sensitive fusion protein attachment protein beta |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of NAPB mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 2:148,535,905...148,574,396
Ensembl chr 2:148,535,905...148,574,387
|
|
G |
Napepld |
N-acyl phosphatidylethanolamine phospholipase D |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of NAPEPLD mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 5:21,867,899...21,906,620
Ensembl chr 5:21,867,899...21,906,394
|
|
G |
Nbea |
neurobeachin |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of NBEA mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 3:55,532,616...56,091,169
Ensembl chr 3:55,532,616...56,091,122
|
|
G |
Ndst3 |
N-deacetylase/N-sulfotransferase (heparan glucosaminyl) 3 |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of NDST3 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 3:123,319,815...123,484,822
Ensembl chr 3:123,319,815...123,484,502
|
|
G |
Necab1 |
N-terminal EF-hand calcium binding protein 1 |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of NECAB1 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 4:14,952,245...15,149,804
Ensembl chr 4:14,952,245...15,149,794
|
|
G |
Nfkb1 |
nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 |
multiple interactions increases expression |
ISO |
[Ivermectin co-treated with Atorvastatin] inhibits the reaction [Poly I-C results in increased expression of NFKB1 mRNA]; Atorvastatin inhibits the reaction [Poly I-C results in increased expression of NFKB1 mRNA]; Ivermectin inhibits the reaction [Poly I-C results in increased expression of NFKB1 mRNA] |
CTD |
PMID:34696514 |
|
NCBI chr 3:135,290,416...135,397,422
Ensembl chr 3:135,290,416...135,397,308
|
|
G |
Nfkbia |
nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha |
increases phosphorylation multiple interactions |
ISO |
Poly I-C results in increased phosphorylation of NFKBIA protein 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased degradation of NFKBIA protein]; [Poly I-C co-treated with IL4 protein] results in increased degradation of NFKBIA protein; amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased degradation of NFKBIA protein]; butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased degradation of NFKBIA protein]; Itraconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased degradation of NFKBIA protein]; Ketoconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased degradation of NFKBIA protein]; luliconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased degradation of NFKBIA protein]; N-(3,5-bis(trifluoromethyl)phenyl)-5-chloro-2-hydroxybenzamide inhibits the reaction [Poly I-C results in increased phosphorylation of NFKBIA protein]; Terbinafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased degradation of NFKBIA protein]; TP53 protein affects the reaction [Poly I-C results in increased phosphorylation of NFKBIA protein] |
CTD |
PMID:18779317 PMID:20932985 PMID:23688403 |
|
NCBI chr12:55,536,194...55,539,432
Ensembl chr12:55,536,195...55,539,432
|
|
G |
Nlgn3 |
neuroligin 3 |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of NLGN3 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr X:100,342,785...100,364,956
Ensembl chr X:100,342,774...100,369,569
|
|
G |
Nmu |
neuromedin U |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in increased expression of NMU mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 5:76,481,342...76,511,624
Ensembl chr 5:76,481,342...76,511,635
|
|
G |
Nos2 |
nitric oxide synthase 2, inducible |
increases expression multiple interactions |
EXP ISO |
Poly I-C results in increased expression of NOS2 mRNA; Poly I-C results in increased expression of NOS2 protein pitavastatin inhibits the reaction [Poly I-C results in increased expression of NOS2 mRNA]; Pravastatin inhibits the reaction [Poly I-C results in increased expression of NOS2 mRNA]; sodium arsenite inhibits the reaction [Poly I-C results in increased expression of NOS2 mRNA]; sodium arsenite inhibits the reaction [Poly I-C results in increased expression of NOS2 protein]; Sodium Selenite inhibits the reaction [Poly I-C results in increased expression of NOS2 protein] Diclofenac promotes the reaction [Poly I-C results in increased expression of NOS2 mRNA] |
CTD |
PMID:17321468 PMID:18279804 PMID:18323514 PMID:21195166 PMID:23939143 PMID:30726814 More...
|
|
NCBI chr11:78,811,613...78,851,052
Ensembl chr11:78,811,613...78,851,080
|
|
G |
Nrsn1 |
neurensin 1 |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of NRSN1 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr13:25,436,022...25,453,979
Ensembl chr13:25,436,023...25,454,485
|
|
G |
Nuf2 |
NUF2, NDC80 kinetochore complex component |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in increased expression of NUF2 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 1:169,325,503...169,359,033
Ensembl chr 1:169,325,503...169,359,033
|
|
G |
Oas1g |
2'-5' oligoadenylate synthetase 1G |
increases expression multiple interactions |
ISO |
Poly I-C results in increased expression of OAS1 mRNA [[Poly I-C co-treated with Interferon-alpha] results in increased activity of OAS1 protein] which results in increased abundance of 2',5'-oligoadenylate; [Poly I-C co-treated with Interferon-alpha] results in increased activity of OAS1 protein; IRF7 protein mutant form inhibits the reaction [Poly I-C results in increased expression of OAS1 mRNA]; Nicotine inhibits the reaction [Poly I-C results in increased expression of OAS1 mRNA] |
CTD |
PMID:17669408 PMID:22240577 PMID:26055709 PMID:31154625 |
|
NCBI chr 5:121,014,205...121,025,676
Ensembl chr 5:121,014,205...121,025,676
|
|
G |
Oas2 |
2'-5' oligoadenylate synthetase 2 |
increases expression |
ISO |
Poly I-C results in increased expression of OAS2 mRNA |
CTD |
PMID:22240577 PMID:22558189 |
|
NCBI chr 5:120,868,398...120,887,949
Ensembl chr 5:120,868,398...120,887,918
|
|
G |
Or4e1 |
olfactory receptor family 4 subfamily E member 1 |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in increased expression of OR4E1 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr14:52,700,178...52,704,918
Ensembl chr14:52,696,286...52,704,952
|
|
G |
P2rx7 |
purinergic receptor P2X, ligand-gated ion channel, 7 |
decreases expression multiple interactions |
EXP |
Poly I-C results in decreased expression of P2RX7 protein Suramin inhibits the reaction [Poly I-C results in decreased expression of P2RX7 protein] |
CTD |
PMID:23516405 |
|
NCBI chr 5:122,781,990...122,830,399
Ensembl chr 5:122,781,974...122,829,495
|
|
G |
P2ry2 |
purinergic receptor P2Y, G-protein coupled 2 |
decreases expression multiple interactions |
EXP |
Poly I-C results in decreased expression of P2RY2 protein Suramin inhibits the reaction [Poly I-C results in decreased expression of P2RY2 protein] |
CTD |
PMID:23516405 |
|
NCBI chr 7:100,645,775...100,661,260
Ensembl chr 7:100,645,775...100,662,073
|
|
G |
Pak2 |
p21 (RAC1) activated kinase 2 |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of PAK2 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr16:31,835,108...31,898,160
Ensembl chr16:31,835,108...31,898,160
|
|
G |
Pard6g |
par-6 family cell polarity regulator gamma |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of PARD6G mRNA |
CTD |
PMID:26923065 |
|
NCBI chr18:80,090,045...80,162,855
Ensembl chr18:80,090,105...80,162,854
|
|
G |
Pcmtd1 |
protein-L-isoaspartate (D-aspartate) O-methyltransferase domain containing 1 |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of PCMTD1 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 1:7,157,301...7,243,852
Ensembl chr 1:7,159,144...7,243,852
|
|
G |
Pdap1 |
PDGFA associated protein 1 |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in increased expression of PDAP1 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 5:145,065,580...145,076,835
Ensembl chr 5:145,065,579...145,077,048
|
|
G |
Pdcd6ip |
programmed cell death 6 interacting protein |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of PDCD6IP mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 9:113,480,812...113,537,457
Ensembl chr 9:113,480,812...113,537,327
|
|
G |
Phactr1 |
phosphatase and actin regulator 1 |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of PHACTR1 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr13:42,833,909...43,292,002
Ensembl chr13:42,834,099...43,292,002
|
|
G |
Phf7 |
PHD finger protein 7 |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in increased expression of PHF7 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr14:30,959,646...30,973,327
Ensembl chr14:30,959,646...30,973,274
|
|
G |
Pkib |
protein kinase inhibitor beta, cAMP dependent, testis specific |
multiple interactions decreases expression |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of PKIB mRNA Poly I-C results in decreased expression of PKIB mRNA |
CTD |
PMID:26923065 |
|
NCBI chr10:57,508,077...57,617,208
Ensembl chr10:57,508,077...57,617,208
|
|
G |
Plcb1 |
phospholipase C, beta 1 |
increases expression |
EXP |
Poly I-C results in increased expression of PLCB1 mRNA |
CTD |
PMID:24889602 |
|
NCBI chr 2:134,628,084...135,317,178
Ensembl chr 2:134,627,987...135,317,178
|
|
G |
Plcxd2 |
phosphatidylinositol-specific phospholipase C, X domain containing 2 |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of PLCXD2 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr16:45,779,624...45,830,776
Ensembl chr16:45,779,626...45,830,581
|
|
G |
Plekha8 |
pleckstrin homology domain containing, family A (phosphoinositide binding specific) member 8 |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in increased expression of PLEKHA8 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 6:54,571,883...54,622,808
Ensembl chr 6:54,572,096...54,622,824
|
|
G |
Plppr4 |
phospholipid phosphatase related 4 |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of PLPPR4 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 3:117,112,794...117,154,525
Ensembl chr 3:117,112,788...117,154,525
|
|
G |
Pmvk |
phosphomevalonate kinase |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in increased expression of PMVK mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 3:89,361,848...89,376,321
Ensembl chr 3:89,361,848...89,376,320
|
|
G |
Pou5f1 |
POU domain, class 5, transcription factor 1 |
increases expression multiple interactions |
ISO |
Poly I-C results in increased expression of POU5F1 protein Poly I-C promotes the reaction [MSI1 protein results in increased expression of POU5F1 protein] |
CTD |
PMID:29486283 |
|
NCBI chr17:35,816,929...35,821,674
Ensembl chr17:35,816,915...35,821,669
|
|
G |
Prf1 |
perforin 1 (pore forming protein) |
multiple interactions increases expression |
ISO |
Particulate Matter inhibits the reaction [Poly I-C results in increased expression of PRF1 protein]; Vehicle Emissions inhibits the reaction [Poly I-C results in increased expression of PRF1 protein] Poly I-C results in increased expression of PRF1 mRNA; Poly I-C results in increased expression of PRF1 protein |
CTD |
PMID:23618096 |
|
NCBI chr10:61,133,530...61,140,463
Ensembl chr10:61,133,612...61,140,459
|
|
G |
Prkci |
protein kinase C, iota |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of PRKCI mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 3:31,049,893...31,106,889
Ensembl chr 3:31,049,896...31,107,108
|
|
G |
Prl2b1 |
prolactin family 2, subfamily b, member 1 |
multiple interactions increases expression |
EXP |
IL6 protein affects the reaction [Poly I-C results in increased expression of PRL2B1 mRNA] |
CTD |
PMID:21195166 |
|
NCBI chr13:27,567,328...27,574,829
Ensembl chr13:27,567,322...27,574,829
|
|
G |
Prodh2 |
proline dehydrogenase (oxidase) 2 |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in increased expression of PRODH2 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 7:30,193,011...30,212,830
Ensembl chr 7:30,193,047...30,212,827
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
increases expression multiple interactions |
EXP |
Poly I-C results in increased expression of PTGS2 protein [Poly I-C results in increased susceptibility to 4-iodo-2,5-dimethoxyphenylisopropylamine] which results in increased expression of PTGS2 mRNA; Poly I-C promotes the reaction [4-iodo-2,5-dimethoxyphenylisopropylamine results in increased expression of PTGS2 mRNA]; Resveratrol inhibits the reaction [Poly I-C results in increased expression of PTGS2 protein]; Sodium Selenite inhibits the reaction [Poly I-C results in increased expression of PTGS2 protein] |
CTD |
PMID:16116226 PMID:18279804 PMID:24889602 |
|
NCBI chr 1:149,975,851...149,983,978
Ensembl chr 1:149,975,782...149,983,978
|
|
G |
Pvalb |
parvalbumin |
multiple interactions |
ISO |
[Poly I-C co-treated with Cannabidiol] results in increased expression of PVALB protein |
CTD |
PMID:31326506 |
|
NCBI chr15:78,075,312...78,090,600
Ensembl chr15:78,075,314...78,090,600
|
|
G |
Rac1 |
Rac family small GTPase 1 |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of RAC1 mRNA [Poly I-C co-treated with Atorvastatin] results in decreased expression of RAC1 mRNA; [Poly I-C co-treated with Ivermectin] results in decreased expression of RAC1 mRNA |
CTD |
PMID:26923065 PMID:34696514 |
|
NCBI chr 5:143,491,236...143,513,786
Ensembl chr 5:143,489,389...143,513,791
|
|
G |
Rarb |
retinoic acid receptor, beta |
multiple interactions |
ISO |
[Arsenicals co-treated with Poly I-C co-treated with Alitretinoin] results in decreased expression of RARB mRNA; [Arsenicals co-treated with Poly I-C co-treated with Alitretinoin] results in decreased expression of RARB protein; [Arsenicals co-treated with Poly I-C] affects the expression of RARB mRNA; [Arsenicals co-treated with Poly I-C] results in decreased expression of RARB protein |
CTD |
PMID:34303791 |
|
NCBI chr14:5,387,365...6,038,924
Ensembl chr14:5,650,540...6,038,924
|
|
G |
Rdm1 |
RAD52 motif 1 |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in increased expression of RDM1 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr11:101,517,992...101,526,926
Ensembl chr11:101,518,021...101,526,926
|
|
G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
affects localization multiple interactions increases phosphorylation |
ISO |
Poly I-C affects the localization of RELA protein TP53 protein affects the reaction [Poly I-C affects the localization of RELA protein] Poly I-C results in increased phosphorylation of RELA protein |
CTD |
PMID:18779317 PMID:24709138 PMID:27836898 |
|
NCBI chr19:5,686,993...5,698,162
Ensembl chr19:5,687,511...5,698,158
|
|
G |
Rgs4 |
regulator of G-protein signaling 4 |
increases expression |
EXP |
Poly I-C results in increased expression of RGS4 mRNA |
CTD |
PMID:24889602 |
|
NCBI chr 1:169,569,046...169,575,211
Ensembl chr 1:169,569,046...169,575,211
|
|
G |
Rhoa |
ras homolog family member A |
multiple interactions |
ISO |
[Poly I-C co-treated with Atorvastatin co-treated with Ivermectin] results in increased expression of RHOA mRNA; [Poly I-C co-treated with Atorvastatin] results in increased expression of RHOA mRNA |
CTD |
PMID:34696514 |
|
NCBI chr 9:108,183,359...108,215,142
Ensembl chr 9:108,183,328...108,215,133
|
|
G |
Rigi |
RNA sensor RIG-I |
increases expression multiple interactions |
ISO |
Poly I-C results in increased expression of RIGI mRNA IRF7 protein mutant form inhibits the reaction [Poly I-C results in increased expression of RIGI mRNA]; Nicotine inhibits the reaction [Poly I-C results in increased expression of RIGI mRNA] |
CTD |
PMID:27183587 PMID:30341573 PMID:31154625 |
|
NCBI chr 4:40,203,775...40,239,843
Ensembl chr 4:40,203,773...40,239,828
|
|
G |
Rimbp2 |
RIMS binding protein 2 |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of RIMBP2 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 5:128,834,852...129,030,636
Ensembl chr 5:128,834,855...129,030,550
|
|
G |
Rimoc1 |
RAB7A interacting MON1-CCZ1 complex subunit 1 |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of RIMOC1 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr15:4,011,517...4,025,228
Ensembl chr15:4,011,517...4,025,226
|
|
G |
Rnf141 |
ring finger protein 141 |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of RNF141 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 7:110,398,676...110,443,659
Ensembl chr 7:110,399,639...110,443,664
|
|
G |
Rpl31 |
ribosomal protein L31 |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in increased expression of RPL31 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 1:39,406,987...39,410,992
Ensembl chr 1:39,406,923...39,410,992
|
|
G |
Rps6kb2 |
ribosomal protein S6 kinase, polypeptide 2 |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in increased expression of RPS6KB2 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr19:4,206,791...4,213,382
Ensembl chr19:4,203,990...4,213,353
|
|
G |
Rtn4rl1 |
reticulon 4 receptor-like 1 |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of RTN4RL1 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr11:75,084,819...75,158,595
Ensembl chr11:75,084,609...75,158,595
|
|
G |
S100a3 |
S100 calcium binding protein A3 |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in increased expression of S100A3 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 3:90,467,571...90,510,922
Ensembl chr 3:90,491,966...90,510,009
|
|
G |
Sema6d |
sema domain, transmembrane domain (TM), and cytoplasmic domain, (semaphorin) 6D |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of SEMA6D mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 2:123,931,089...124,509,711
Ensembl chr 2:123,931,889...124,509,690
|
|
G |
Septin6 |
septin 6 |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of SEPTIN6 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr X:36,174,925...36,253,711
Ensembl chr X:36,174,979...36,255,447
|
|
G |
Serpine1 |
serine (or cysteine) peptidase inhibitor, clade E, member 1 |
multiple interactions increases expression |
ISO |
Chloroquine inhibits the reaction [Poly I-C results in increased expression of SERPINE1 mRNA]; Chloroquine inhibits the reaction [Poly I-C results in increased expression of SERPINE1 protein]; Hydroxychloroquine inhibits the reaction [Poly I-C results in increased expression of SERPINE1 mRNA]; Hydroxychloroquine inhibits the reaction [Poly I-C results in increased expression of SERPINE1 protein]; TLR3 mRNA promotes the reaction [Poly I-C results in increased expression of SERPINE1 mRNA] Poly I-C results in increased expression of SERPINE1 mRNA; Poly I-C results in increased expression of SERPINE1 protein |
CTD |
PMID:30341573 |
|
NCBI chr 5:137,090,358...137,101,126
Ensembl chr 5:137,090,358...137,101,122
|
|
G |
Sesn2 |
sestrin 2 |
increases expression |
EXP |
Poly I-C results in increased expression of SESN2 mRNA |
CTD |
PMID:25637945 |
|
NCBI chr 4:132,220,115...132,237,767
Ensembl chr 4:132,219,343...132,237,812
|
|
G |
Sgtb |
small glutamine-rich tetratricopeptide repeat (TPR)-containing, beta |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of SGTB mRNA |
CTD |
PMID:26923065 |
|
NCBI chr13:104,246,233...104,278,369
Ensembl chr13:104,246,249...104,278,243
|
|
G |
Sh3rf1 |
SH3 domain containing ring finger 1 |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of SH3RF1 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 8:61,677,117...61,918,327
Ensembl chr 8:61,676,906...61,849,105
|
|
G |
Shroom2 |
shroom family member 2 |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of SHROOM2 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr X:151,392,505...151,553,784
Ensembl chr X:151,392,505...151,552,461
|
|
G |
Sidt1 |
SID1 transmembrane family, member 1 |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of SIDT1 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr16:44,060,540...44,153,575
Ensembl chr16:44,060,543...44,153,559
|
|
G |
Slc14a1 |
solute carrier family 14 (urea transporter), member 1 |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of SLC14A1 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr18:78,143,306...78,185,334
Ensembl chr18:78,143,306...78,185,334
|
|
G |
Slc17a7 |
solute carrier family 17 (sodium-dependent inorganic phosphate cotransporter), member 7 |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of SLC17A7 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 7:44,813,345...44,825,563
Ensembl chr 7:44,813,373...44,825,566
|
|
G |
Slc25a12 |
solute carrier family 25 (mitochondrial carrier, Aralar), member 12 |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of SLC25A12 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 2:71,104,614...71,198,125
Ensembl chr 2:71,101,407...71,198,093
|
|
G |
Slc25a14 |
solute carrier family 25 (mitochondrial carrier, brain), member 14 |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of SLC25A14 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr X:47,712,333...47,751,171
Ensembl chr X:47,712,290...47,751,171
|
|
G |
Slc2a13 |
solute carrier family 2 (facilitated glucose transporter), member 13 |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of SLC2A13 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr15:91,151,894...91,457,467
Ensembl chr15:91,151,899...91,457,464
|
|
G |
Slc3a1 |
solute carrier family 3, member 1 |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of SLC3A1 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr17:85,335,775...85,371,669
Ensembl chr17:85,335,804...85,371,664
|
|
G |
Slc4a10 |
solute carrier family 4, sodium bicarbonate cotransporter-like, member 10 |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of SLC4A10 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 2:61,876,815...62,157,087
Ensembl chr 2:61,876,806...62,157,074
|
|
G |
Smarcd1 |
SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily d, member 1 |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of SMARCD1 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr15:99,600,175...99,611,872
Ensembl chr15:99,600,010...99,611,872
|
|
G |
Snd1 |
staphylococcal nuclease and tudor domain containing 1 |
affects localization |
ISO |
Poly I-C affects the localization of SND1 protein |
CTD |
PMID:22240577 |
|
NCBI chr 6:28,480,332...28,935,161
Ensembl chr 6:28,475,138...28,935,161
|
|
G |
Snrk |
SNF related kinase |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of SNRK mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 9:121,946,332...121,998,768
Ensembl chr 9:121,946,332...121,998,768
|
|
G |
Socs1 |
suppressor of cytokine signaling 1 |
increases expression multiple interactions |
EXP |
Poly I-C results in increased expression of SOCS1 mRNA Progesterone promotes the reaction [Poly I-C results in increased expression of SOCS1 mRNA] |
CTD |
PMID:22546503 |
|
NCBI chr16:10,601,672...10,603,400
Ensembl chr16:10,600,104...10,603,400
|
|
G |
Socs3 |
suppressor of cytokine signaling 3 |
increases expression |
EXP |
Poly I-C results in increased expression of SOCS3 mRNA |
CTD |
PMID:21195166 |
|
NCBI chr11:117,856,905...117,860,192
Ensembl chr11:117,856,905...117,860,873
|
|
G |
Sod2 |
superoxide dismutase 2, mitochondrial |
increases expression |
ISO |
Poly I-C results in increased expression of SOD2 mRNA |
CTD |
PMID:23939143 |
|
NCBI chr17:13,226,726...13,237,006
Ensembl chr17:13,225,733...13,258,950
|
|
G |
Sox2 |
SRY (sex determining region Y)-box 2 |
increases expression multiple interactions |
ISO |
Poly I-C results in increased expression of SOX2 protein Poly I-C promotes the reaction [MSI1 protein results in increased expression of SOX2 protein] |
CTD |
PMID:29486283 |
|
NCBI chr 3:34,704,144...34,706,610
Ensembl chr 3:34,704,554...34,706,610
|
|
G |
Spag6 |
sperm associated antigen 6 |
decreases expression |
ISO |
Poly I-C results in decreased expression of SPAG6 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 2:18,698,808...18,754,561
Ensembl chr 2:18,698,843...18,755,224
|
|
G |
Srsf12 |
serine and arginine-rich splicing factor 12 |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of SRSF12 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 4:33,208,991...33,233,344
Ensembl chr 4:33,208,991...33,233,340
|
|
G |
Srsf7 |
serine and arginine-rich splicing factor 7 |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of SRSF7 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr17:80,507,509...80,514,734
Ensembl chr17:80,507,509...80,514,736
|
|
G |
Stat1 |
signal transducer and activator of transcription 1 |
increases phosphorylation multiple interactions increases expression |
EXP ISO |
Poly I-C results in increased phosphorylation of STAT1 protein sodium arsenite inhibits the reaction [Poly I-C results in increased phosphorylation of STAT1 protein] IRF7 protein mutant form inhibits the reaction [Poly I-C results in increased expression of STAT1 mRNA]; Nicotine inhibits the reaction [Poly I-C results in increased expression of STAT1 mRNA] |
CTD |
PMID:30726814 PMID:31154625 |
|
NCBI chr 1:52,158,588...52,201,024
Ensembl chr 1:52,158,599...52,201,024
|
|
G |
Stat2 |
signal transducer and activator of transcription 2 |
increases expression multiple interactions |
ISO |
Poly I-C results in increased expression of STAT2 mRNA IRF7 protein mutant form inhibits the reaction [Poly I-C results in increased expression of STAT2 mRNA] |
CTD |
PMID:31154625 |
|
NCBI chr10:128,106,367...128,128,722
Ensembl chr10:128,106,428...128,128,718
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
multiple interactions |
EXP |
IL6 protein affects the reaction [Poly I-C results in increased phosphorylation of and results in increased activity of STAT3 protein]; Poly I-C results in increased phosphorylation of and results in increased activity of STAT3 protein |
CTD |
PMID:21195166 |
|
NCBI chr11:100,777,632...100,830,447
Ensembl chr11:100,775,924...100,830,366
|
|
G |
Stxbp6 |
syntaxin binding protein 6 (amisyn) |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of STXBP6 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr12:44,899,267...45,121,248
Ensembl chr12:44,899,267...45,121,492
|
|
G |
Svip |
small VCP/p97-interacting protein |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of SVIP mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 7:51,646,909...51,655,766
Ensembl chr 7:51,646,919...51,655,766
|
|
G |
Syt11 |
synaptotagmin XI |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of SYT11 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 3:88,652,006...88,682,466
Ensembl chr 3:88,652,007...88,682,471
|
|
G |
Tbc1d9 |
TBC1 domain family, member 9 |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of TBC1D9 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 8:83,891,981...83,999,569
Ensembl chr 8:83,891,981...83,999,563
|
|
G |
Tbk1 |
TANK-binding kinase 1 |
multiple interactions increases phosphorylation |
EXP |
APPL1 protein promotes the reaction [Poly I-C results in increased phosphorylation of TBK1 protein]; bafilomycin A1 promotes the reaction [Poly I-C results in increased phosphorylation of TBK1 protein] |
CTD |
PMID:25780039 |
|
NCBI chr10:121,382,360...121,422,699
Ensembl chr10:121,382,360...121,422,692
|
|
G |
Tfb1m |
transcription factor B1, mitochondrial |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in increased expression of TFB1M mRNA |
CTD |
PMID:26923065 |
|
NCBI chr17:3,569,119...3,608,064
Ensembl chr17:3,569,531...3,608,056
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
increases secretion |
ISO |
Poly I-C results in increased secretion of TGFB1 protein |
CTD |
PMID:34740670 |
|
NCBI chr 7:25,386,406...25,404,503
Ensembl chr 7:25,386,427...25,404,502
|
|
G |
Thy1 |
thymus cell antigen 1, theta |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of THY1 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 9:43,954,681...43,959,876
Ensembl chr 9:43,954,681...43,959,876
|
|
G |
Tial1 |
Tia1 cytotoxic granule-associated RNA binding protein-like 1 |
affects localization |
ISO |
Poly I-C affects the localization of TIAL1 protein |
CTD |
PMID:22240577 |
|
NCBI chr 7:128,041,496...128,063,450
Ensembl chr 7:128,041,501...128,063,441
|
|
G |
Ticam1 |
TIR domain containing adaptor molecule 1 |
increases expression |
ISO |
Poly I-C results in increased expression of TICAM1 mRNA |
CTD |
PMID:21418039 |
|
NCBI chr17:56,576,462...56,583,767
Ensembl chr17:56,576,319...56,583,786
|
|
G |
Timp1 |
tissue inhibitor of metalloproteinase 1 |
increases expression |
EXP |
Poly I-C results in increased expression of TIMP1 mRNA |
CTD |
PMID:21195166 |
|
NCBI chr X:20,736,524...20,740,972
Ensembl chr X:20,736,405...20,740,974
|
|
G |
Tlr2 |
toll-like receptor 2 |
increases expression |
ISO |
Poly I-C results in increased expression of TLR2 mRNA |
CTD |
PMID:17669408 |
|
NCBI chr 3:83,743,579...83,749,045
Ensembl chr 3:83,743,579...83,749,074
|
|
G |
Tlr3 |
toll-like receptor 3 |
multiple interactions increases expression increases activity |
ISO EXP |
[[Poly I-C binds to and results in increased activity of TLR3 protein] which co-treated with Nanotubes, Carbon] results in increased secretion of IL12B protein; [[Poly I-C binds to and results in increased activity of TLR3 protein] which co-treated with Nanotubes, Carbon] results in increased secretion of TNF protein; [Poly I-C binds to TLR3 protein] which affects the susceptibility to 1-aminopyrene; [Poly I-C binds to TLR3 protein] which affects the susceptibility to 1-nitropyrene; [Poly I-C binds to TLR3 protein] which affects the susceptibility to pyrene; [Vehicle Emissions analog co-treated with Poly I-C] results in increased expression of TLR3 mRNA; [Vehicle Emissions analog co-treated with Poly I-C] results in increased expression of TLR3 protein; Chloroquine inhibits the reaction [Poly I-C results in increased activity of TLR3 protein]; Poly I-C binds to and results in increased activity of TLR3 protein; Quinacrine inhibits the reaction [Poly I-C results in increased activity of TLR3 protein]; TLR3 mRNA promotes the reaction [Poly I-C results in increased expression of IL6 mRNA]; TLR3 mRNA promotes the reaction [Poly I-C results in increased expression of SERPINE1 mRNA]; TLR3 protein affects the reaction [Poly I-C results in increased expression of CXCL8 mRNA]; TLR3 protein affects the reaction [Poly I-C results in increased expression of IFNB1 mRNA] Poly I-C results in increased expression of TLR3 mRNA cinnamaldehyde inhibits the reaction [Poly I-C results in increased expression of TLR3 mRNA] MIR26A mRNA inhibits the reaction [Poly I-C results in increased activity of TLR3 protein] |
CTD |
PMID:16399790 PMID:17669408 PMID:18306459 PMID:18779317 PMID:21398612 PMID:21418039 PMID:23266719 PMID:23458896 PMID:24423102 PMID:25780039 PMID:26682054 PMID:27385120 PMID:28003376 PMID:30341573 PMID:32244040 More...
|
|
NCBI chr 8:45,848,702...45,864,112
Ensembl chr 8:45,848,702...45,864,117
|
|
G |
Tlr7 |
toll-like receptor 7 |
increases expression |
ISO |
Poly I-C results in increased expression of TLR7 mRNA |
CTD |
PMID:17669408 |
|
NCBI chr X:166,086,376...166,113,570
Ensembl chr X:166,087,925...166,113,554
|
|
G |
Tmem266 |
transmembrane protein 266 |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in increased expression of TMEM266 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 9:55,234,194...55,345,629
Ensembl chr 9:55,234,197...55,345,629
|
|
G |
Tmem273 |
transmembrane protein 273 |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in increased expression of TMEM273 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr14:32,507,869...32,539,926
Ensembl chr14:32,507,920...32,539,941
|
|
G |
Tmprss2 |
transmembrane protease, serine 2 |
decreases response to substance |
EXP |
TMPRSS2 gene mutant form results in decreased susceptibility to Poly I-C |
CTD |
PMID:30626688 |
|
NCBI chr16:97,365,882...97,460,741
Ensembl chr16:97,365,882...97,412,395
|
|
G |
Tmx1 |
thioredoxin-related transmembrane protein 1 |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of TMX1 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr12:70,499,928...70,514,398
Ensembl chr12:70,499,869...70,514,814
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions increases secretion increases expression |
ISO EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane promotes the reaction [Poly I-C results in increased expression of TNF protein]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Poly I-C results in increased secretion of TNF protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Poly I-C results in increased secretion of TNF protein]; 4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol promotes the reaction [Poly I-C results in increased expression of TNF protein]; [[Poly I-C binds to and results in increased activity of TLR3 protein] which co-treated with Nanotubes, Carbon] results in increased secretion of TNF protein; CEP-11004 inhibits the reaction [Poly I-C results in increased secretion of TNF protein]; CpG ODN 2006 inhibits the reaction [Poly I-C results in increased secretion of TNF protein]; Estradiol promotes the reaction [Poly I-C results in increased expression of TNF protein]; N-(3,5-bis(trifluoromethyl)phenyl)-5-chloro-2-hydroxybenzamide inhibits the reaction [Poly I-C results in increased secretion of TNF protein]; pyrazolanthrone inhibits the reaction [Poly I-C results in increased secretion of TNF protein]; RTKI cpd inhibits the reaction [Poly I-C results in increased secretion of TNF protein]; SB 203580 inhibits the reaction [Poly I-C results in increased secretion of TNF protein] APPL1 protein inhibits the reaction [Poly I-C results in increased expression of TNF protein]; Citrinin inhibits the reaction [Poly I-C results in increased expression of TNF mRNA]; Citrinin inhibits the reaction [Poly I-C results in increased expression of TNF protein]; Cycloheximide inhibits the reaction [Poly I-C results in increased secretion of TNF protein]; Dimethyl Sulfoxide inhibits the reaction [Poly I-C results in increased secretion of TNF protein]; Ethanol inhibits the reaction [Poly I-C results in increased expression of TNF mRNA]; Ethanol inhibits the reaction [Poly I-C results in increased expression of TNF protein]; Ethanol inhibits the reaction [Poly I-C results in increased secretion of TNF protein]; Ethanol promotes the reaction [Hydroxamic Acids analog promotes the reaction [Dimethyl Sulfoxide inhibits the reaction [Poly I-C results in increased secretion of TNF protein]]]; Hydroxamic Acids analog inhibits the reaction [Poly I-C results in increased secretion of TNF protein]; Hydroxamic Acids analog promotes the reaction [Dimethyl Sulfoxide inhibits the reaction [Poly I-C results in increased secretion of TNF protein]]; Luteolin inhibits the reaction [Poly I-C results in increased expression of TNF mRNA]; Poly I-C promotes the reaction [deoxynivalenol results in increased expression of TNF mRNA]; sodium arsenite inhibits the reaction [Poly I-C results in increased expression of TNF mRNA] Poly I-C results in increased expression of TNF mRNA; Poly I-C results in increased expression of TNF protein cyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl ester inhibits the reaction [Poly I-C results in increased expression of TNF mRNA]; MIR26A mRNA inhibits the reaction [Poly I-C results in increased expression of TNF mRNA]; MIR26A mRNA inhibits the reaction [Poly I-C results in increased expression of TNF protein] |
CTD |
PMID:16687389 PMID:17238832 PMID:17321468 PMID:17669408 PMID:17698565 PMID:17868967 PMID:18323514 PMID:19426678 PMID:19500611 PMID:20932985 PMID:22319556 PMID:22771370 PMID:23266719 PMID:23618096 PMID:23939143 PMID:24423102 PMID:25780039 PMID:27385120 PMID:28316773 PMID:28726298 PMID:30017638 PMID:30726814 PMID:30836164 PMID:36958387 More...
|
|
NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983
|
|
G |
Tnfsf10 |
tumor necrosis factor (ligand) superfamily, member 10 |
increases expression |
EXP |
Poly I-C results in increased expression of TNFSF10 mRNA; Poly I-C results in increased expression of TNFSF10 protein |
CTD |
PMID:16472598 |
|
NCBI chr 3:27,371,226...27,393,814
Ensembl chr 3:27,371,177...27,396,576
|
|
G |
Tnks2 |
tankyrase, TRF1-interacting ankyrin-related ADP-ribose polymerase 2 |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of TNKS2 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr19:36,811,583...36,870,877
Ensembl chr19:36,811,632...36,870,877
|
|
G |
Tpd52 |
tumor protein D52 |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of TPD52 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 3:8,991,590...9,069,824
Ensembl chr 3:8,990,653...9,069,783
|
|
G |
Tpk1 |
thiamine pyrophosphokinase |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of TERF2IP mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 6:43,316,510...43,644,726
Ensembl chr 6:43,321,935...43,643,212
|
|
G |
Traf6 |
TNF receptor-associated factor 6 |
multiple interactions |
ISO |
TRAF6 mutant form inhibits the reaction [Vehicle Emissions analog promotes the reaction [Poly I-C results in increased expression of IL6 mRNA]] |
CTD |
PMID:16399790 |
|
NCBI chr 2:101,508,765...101,532,013
Ensembl chr 2:101,508,774...101,532,014
|
|
G |
Trim2 |
tripartite motif-containing 2 |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of TRIM2 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 3:84,067,746...84,215,659
Ensembl chr 3:84,067,746...84,214,184
|
|
G |
Trp53 |
transformation related protein 53 |
multiple interactions |
ISO |
TP53 protein affects the reaction [Poly I-C affects the localization of RELA protein]; TP53 protein affects the reaction [Poly I-C results in increased expression of CXCL8 mRNA]; TP53 protein affects the reaction [Poly I-C results in increased expression of IFNB1 mRNA]; TP53 protein affects the reaction [Poly I-C results in increased phosphorylation of IRF3 protein]; TP53 protein affects the reaction [Poly I-C results in increased phosphorylation of NFKBIA protein]; TP53 results in increased susceptibility to [Poly I-C co-treated with Fluorouracil] |
CTD |
PMID:18779317 PMID:20367642 |
|
NCBI chr11:69,471,174...69,482,699
Ensembl chr11:69,471,185...69,482,699
|
|
G |
Tslp |
thymic stromal lymphopoietin |
multiple interactions increases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]; 4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol promotes the reaction [Poly I-C results in increased expression of TSLP protein]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [Itraconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [Itraconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [Ketoconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [Ketoconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [luliconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [luliconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [Terbinafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [Terbinafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]]; [Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA; [Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein; amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]; amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]; butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]; butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]; Estradiol promotes the reaction [Poly I-C results in increased expression of TSLP protein]; helenalin inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]; helenalin inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]; IL4 protein promotes the reaction [Poly I-C results in increased expression of TSLP mRNA]; IL4 protein promotes the reaction [Poly I-C results in increased expression of TSLP protein]; Itraconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]; Itraconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]; Ketoconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]; Ketoconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]; luliconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]; luliconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]; Terbinafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]; Terbinafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein] Poly I-C results in increased expression of TSLP mRNA; Poly I-C results in increased expression of TSLP protein |
CTD |
PMID:23688403 PMID:30017638 |
|
NCBI chr18:32,948,436...32,952,852
Ensembl chr18:32,948,436...32,952,850
|
|
G |
Tspyl5 |
testis-specific protein, Y-encoded-like 5 |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of TSPYL5 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr15:33,684,021...33,688,029
Ensembl chr15:33,684,021...33,688,030
|
|
G |
Ttc3 |
tetratricopeptide repeat domain 3 |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of TTC3 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr16:94,171,479...94,270,081
Ensembl chr16:94,171,477...94,270,202
|
|
G |
Twist1 |
twist basic helix-loop-helix transcription factor 1 |
decreases expression |
ISO |
Poly I-C results in decreased expression of TWIST1 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr12:34,007,670...34,009,830
Ensembl chr12:34,007,670...34,009,828
|
|
G |
Twsg1 |
twisted gastrulation BMP signaling modulator 1 |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of TWSG1 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr17:66,230,060...66,258,198
Ensembl chr17:66,228,967...66,258,221
|
|
G |
Txn1 |
thioredoxin 1 |
multiple interactions increases expression |
ISO |
Diclofenac inhibits the reaction [Poly I-C results in increased expression of TXN1 mRNA] |
CTD |
PMID:23939143 |
|
NCBI chr 4:57,943,373...57,956,411
Ensembl chr 4:57,943,373...57,956,411
|
|
G |
Ubl4a |
ubiquitin-like 4A |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of UBL4A mRNA |
CTD |
PMID:26923065 |
|
NCBI chr X:73,409,324...73,412,154
Ensembl chr X:73,409,324...73,416,824
|
|
G |
Ubr1 |
ubiquitin protein ligase E3 component n-recognin 1 |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of UBR1 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 2:120,690,753...120,801,246
Ensembl chr 2:120,690,750...120,801,196
|
|
G |
Ugt2b1 |
UDP glucuronosyltransferase 2 family, polypeptide B1 |
decreases expression |
ISO |
Poly I-C results in decreased expression of UGT2B1 mRNA |
CTD |
PMID:23939143 |
|
NCBI chr 5:87,064,498...87,074,362
Ensembl chr 5:87,064,497...87,074,389
|
|
G |
Usp32 |
ubiquitin specific peptidase 32 |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of USP32 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr11:84,875,263...85,031,107
Ensembl chr11:84,875,268...85,030,987
|
|
G |
Vsnl1 |
visinin-like 1 |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of VSNL1 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr12:11,375,258...11,486,579
Ensembl chr12:11,375,243...11,486,614
|
|
G |
Wac |
WW domain containing adaptor with coiled-coil |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of WAC mRNA |
CTD |
PMID:26923065 |
|
NCBI chr18:7,868,614...7,929,028
Ensembl chr18:7,868,832...7,929,028
|
|
G |
Wdr47 |
WD repeat domain 47 |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of WDR47 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 3:108,498,302...108,553,035
Ensembl chr 3:108,498,595...108,553,035
|
|
G |
Zbtb6 |
zinc finger and BTB domain containing 6 |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of ZBTB6 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 2:37,315,512...37,320,931
Ensembl chr 2:37,315,512...37,333,183
|
|
G |
Zdhhc21 |
zinc finger, DHHC domain containing 21 |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of ZDHHC21 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 4:82,716,975...82,778,892
Ensembl chr 4:82,716,975...82,778,195
|
|
G |
Zfp354c |
zinc finger protein 354C |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of ZFP354C mRNA |
CTD |
PMID:26923065 |
|
NCBI chr11:50,701,912...50,718,558
Ensembl chr11:50,701,913...50,718,551
|
|
G |
Zfp763 |
zinc finger protein 763 |
multiple interactions |
ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of ZFP763 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr17:33,235,838...33,252,355
Ensembl chr17:33,235,837...33,252,376
|
|